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CHAPTER 1  
GENERAL INTRODUCTION TO MYCOTOXINS 
 
 
1.1 DEFINITION OF MYCOTOXINS 
 
Mycotoxins are secondary metabolites produced by fungi. These naturally occurring toxins 
are not associated with fungal growth, but are a consequence of the fungus responding to 
signals from the environment (Moss, 1991). Mycotoxins are produced under specific 
conditions of moisture and temperature and are generally associated with diseased or 
mouldy crops. Not all fungi can produce mycotoxins, and even those with the ability to 
produce mycotoxins may not produce them all the time. Fungi can contaminate crops with 
mycotoxins on the field (pre-harvest) or during transport, storage or processing (post-harvest) 
with Aspergillus, Penicillium and Fusarium as main producers. Mycotoxins are physically and 
chemically very stable and tend to survive storage and food processing even at extreme 
temperatures. Nevertheless, those that do occur in food have great impact on the health of 
humans and can cause significant economic losses in terms of plants and livestock.  
 
Mycotoxins form a worldwide problem as they are present in more than 25 % of the 
worldwide crops (CAST, 2003). Mycotoxins occur in different food commodities such as 
cereals, nuts, (dried) fruit, coffee, spices, seeds or beans and are responsible for a diverse 
range of toxic effects because of their different chemical structures. While exposure through 
ingestion of contaminated food is numerously reported, inhalation and skin contact can also 
be a direct route of exposure (Hendry and Cole, 1993; Pitt et al., 2000). Furthermore, people 
can also be exposed to mycotoxins by the consumption of animal derived products such as 
meat, eggs or milk (carry-over). Exposure to toxic fungal metabolites causes diseases 
collectively called mycotoxicoses which can be categorised as acute or chronic (Forgacs, 
1962). Acute toxicity generally has a rapid onset and an obvious toxic response. It requires 
[CHAPTER 1]  GENERAL INTRODUCTION TO MYCOTOXINS 
 
 
4 | 
high amounts of toxin present in food being consumed and such incidents are usually 
restricted to the less developed parts of the world where resources for control are limited 
(Bennett and Klich, 2003). Chronic effects are caused by the exposure of a low level of toxin 
in the body over a long period of time and can affect the long-term health of the population 
(James, 1985). Mycotoxins can be carcinogenic, genotoxic or may target kidney, liver or 
immune system (see chapter 2). The magnitude of effect is influenced by many factors such 
as dose, duration of exposure, age and health status of the exposed individual (Bennett and 
Klich, 2003). The toxicity and mode of action of mycotoxins is complex due to the conversion 
into metabolites which can lead to bioactivation or inactivation (see chapter 2). Since fungal 
species are able to produce more than one mycotoxin there could be an additive, synergetic 
or antagonistic effect (Speijers and Speijers, 2004).  
 
Mycotoxin exposure differs around the world, depending on the climate. In general, in 
developing countries where poor methods of food handling and storage are common and 
where only a few or no regulations exist, mycotoxin exposure is more likely to occur 
(Bennett and Klich, 2003). However, even in developed countries, specific subgroups may be 
vulnerable to mycotoxin exposure. As climate change affects environmental factors, this 
could have an important impact on mycotoxin contamination (Miraglia et al., 2009). 
Methods for controlling mycotoxins are largely preventive. None of these methods has 
solved the problem, because mycotoxin formation is often unavoidable. Many efforts to 
address the mycotoxin problem simply involve the elimination of mycotoxin contaminated 
commodities from the food supply through government screening and regulatory programs. 
Still the economic losses, the risk for animal and human health are underestimated.  
 
1.2 MAJOR MYCOTOXINS 
  
The term mycotoxin was coined in 1962 after the death of 100 000 turkeys in England.  
When this mysterious turkey X disease was linked to a peanut meal contaminated with 
secondary metabolites from A. flavus (aflatoxins), it sensitised scientists to the possibility 
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that other unknown mold metabolites might be deadly (Blout, 1961; Forgacs, 1962). For this 
reason, the period between 1960 and 1975 has been termed the mycotoxin gold rush 
(Maggon et al., 1977). Many scientists joined the well-funded search for these toxigenic 
agents. The turkey X disease was not the first disease caused by exposure to mycotoxins. 
Ergotism was common in the Middle Ages. It is also known as Saint Anthony’s Fire and was 
caused by the ingestion of ergot alkaloids produced by Claviceps species. Ergotism can be 
roughly divided in two forms namely the gangrenous form that affects the blood supply to 
the extremities while the convulsive form affects the central nervous system (Bennett and 
Bentley, 1999). Another example of a historical mycotoxicosis is Alimentary Toxic Aleukia 
(ATA). ATA affected a large part of the Russian population during World War II with 
symptoms including inflammation of the skin, vomiting and central nervous system disorders. 
ATA was caused by food contaminated with trichothecenes (Matossian, 1981). More 
recently, mycotoxins were linked to the sick-building syndrome. Poor ventilation, water 
damage and molds in indoor environments are responsible for irritation of the eyes and 
respiratory tract (Nielsen et al., 1999). Currently more than 400 mycotoxins are identified. 
Within the scope of this doctoral thesis the most abundant mycotoxins are described with 
emphasis on those with available (potential) biomarkers of exposure. 
 
1.2.1 Aflatoxins 
 
Aflatoxins are difuranocoumarin derivatives (figure 1.1.) produced by a polyketide pathway 
by many species of Aspergillus such as A. flavus and A. parasiticus (Peterson et al., 2001). 
Aflatoxins predominantly occur in hot and humid regions of the world and contaminate 
dietary staples including maize and groundnuts. Sometimes crops become contaminated 
with aflatoxins in the field before harvest, where it is usually associated with drought stress 
(Diener et al., 1987). Higher levels of fungal growth and toxin production often occur during 
storage where moisture content of the substrate and the relative humidity of the 
surroundings are the most important variables (Wilson and Payne, 1994). The four major 
aflatoxins are called aflatoxin B1 (AFB1), aflatoxin B2 (AFB2), aflatoxin G1 (AFG1), and aflatoxin 
G2 (AFG2), based on their fluorescence under UV light (blue or green), with AFB1 being the 
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most toxic and carcinogenic within this group (Squire, 1981). Furthermore, AFB1 can be 
hydroxylated to aflatoxin M1 (AFM1), which is a frequent metabolite in milk of exposed 
lactating animals, including in human breast milk after maternal exposure to dietary AFB1 
(Wild and Gong, 2010).  
 
 
Figure 1.1. Structure of aflatoxin B1 (A), aflatoxin B2 (B), aflatoxin G1 (C), aflatoxin G2 (D) and aflatoxin M1 (E) 
 
1.2.2 Citrinin 
 
Citrinin (CIT) was first isolated from P. citrinum prior to World War II (Hetherington and 
Raistrick, 1931). Subsequently, it was identified in different species of Penicillium and 
Aspergillus. More recently, CIT has also been isolated from Monascus ruber and M. 
purpureus, industrial species used to produce red pigments (Blanc et al., 1995). CIT is 
associated with the yellow rice disease in Japan (Saito et al., 1971) and can be found in 
wheat, oats, rye, maize, barley and rice (Abramson et al., 2001). CIT was also detected in 
certain vegetarian foods colored with Monascus pigments (Chu, 1991). CIT has structural 
similarities (figure 1.2.) with ochratoxin A (OTA) that could explain the similar toxicological 
effects and their additive mechanisms (Bennett and Klich, 2003; Chang et al., 2011).  
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Figure 1.2. Structure of citrinin 
 
1.2.3 Fumonisins 
 
Fumonisins are a family of mycotoxins produced by the fungi F. verticillioides and F. 
proliferatum (Rheeder et al., 2002). Fumonisins were first described and characterised in 
1988 (Gelderblom et al., 1988). Fumonisins predominantly contaminate maize in hot and 
humid climates, and co-contamination with aflatoxins is reported. Unlike most known 
mycotoxins, which are soluble in organic solvents, fumonisins are hydrophilic (figure 1.3.). 
The fumonisin story raises the specter that there may be many other unknown toxic 
products of fungal metabolism that have not yet been discovered because of their 
hydrophilic nature. Fumonisin B1 (FB1), fumonisin B2 (FB2) and fumonisin B3 (FB3) are most 
commonly detected in maize and FB1 is recognised as the most toxic fumonisin (Bennett and 
Klich, 2003).  
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Figure 1.3. Structure of fumonisin B1 (A), fumonisin B2 (B) and fumonisin B3 (C) 
 
1.2.4 Ochratoxins 
 
Members of the ochratoxin family (figure 1.4.) have been found as metabolites of many 
different species of Aspergillus and Penicillium. The ochratoxins are pentaketides made up of 
dihydro-isocoumarin linked to β-phenylalanine and consist of OTA, its methyl ester, its ethyl 
ester better known as ochratoxin C (OTC), ochratoxin B (OTB) and its methyl- and ethyl 
esters. OTA is the most toxic member in this group and was discovered as a metabolite of A. 
ochraceus in 1965 during a large screening of fungal metabolites that was designed 
specifically to identify new mycotoxins (Van der Merwe et al., 1965). In temperate regions, 
OTA is mainly produced by P. verrucosum, a common contaminant of barley (Pitt, 1987). The 
production of OTA during storage is the most important factor of OTA contamination in food. 
It has been found in barley, oats, rye, wheat, coffee beans and other plant products. There is 
also concern that OTA may be present in certain wines, especially those from grapes 
contaminated with A. carbonarius (Marquardt and Frohlich, 1992; Pitt, 2000).  
 
 
[CHAPTER 1]  GENERAL INTRODUCTION TO MYCOTOXINS 
 
 
| 9  
 
Figure 1.4. Structure of ochratoxin A (A), ochratoxin B (B) and ochratoxin C (C) 
 
1.2.5 Trichothecenes 
 
Trichothecenes are a family of mycotoxins that consists of more than 60 sesquiterpenoid 
metabolites produced by several Fusarium fungi that contaminate cereal crops throughout 
the world  (Ueno, 1983). The term trichothecene is derived from trichothecin, which was one 
of the first members of the family identified. All trichothecenes contain a common 12,13-
epoxytrichothene skeleton and an olefinic bond with various side chain substitutions (figure 
1.5.). Trichothecenes are classified as macrocylic or nonmacrocyclic, depending on the 
presence of a macrocylic ester or an ester-ether bridge between C-4 and C-15 (Chu, 1998). 
The nonmacrocylic trichothecenes can be subclassified into two groups: type A, which have a 
hydrogen or ester type side chain at the C-8 position, and include T-2 toxin (T-2) and 
diacetoxyscirpenol (DAS), while the type B group contains a ketone and includes fusarenon X 
(FusX) and deoxynivalenol (DON). DON and T-2 are the best studied of the trichothecenes 
produced by Fusarium species. F. graminearum and F. culmorum infection of wheat and 
maize in more temperate regions causes significant economic loss in the form of head blight 
and contamination of DON and other trichothecene mycotoxins. DON, also known as 
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vomitoxin, is the most prevalent and is commonly found in barley, maize, rye, wheat and 
mixed feeds (Bennett and Klich, 2003). A survey within the European Union (EU) revealed 
that 44 % of food samples tested were contaminated with DON, demonstrating the frequent 
contamination (EFSA, 2013).  
 
 
 
A B 
 
 
C D 
Figure 1.5. Structure of trichothecene mycotoxins deoxynivalenol (A), diacetoxyscirpenol (B), fusarenon X (C) 
and T-2 toxin (D)  
 
1.2.6 Zearalenone 
 
Zearalenone (ZEN) is a secondary metabolite of F. graminearum and F. culmorum. These 
species are regular contaminants of cereal crops worldwide (Hagler et al., 2001) and occur 
most of the time in temperate climates. ZEN and DON can contaminate crops simultaneously. 
The structure of ZEN is similar to 17β-estradiol, an important hormone produced by ovary of 
women, and is therefore better classified as a nonsteroidal estrogen or mycoestrogen (figure 
1.6.). ZEN mainly contaminates maize, wheat, barley, oats and rye (Kuiper-Goodman et al., 
1987). 
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Figure 1.6. Structure of zearalenone 
 
1.2.7 Modified mycotoxins 
 
The term ‘masked mycotoxins’ has been introduced by Gareis et al. (1990) to describe 
zearalenone-14-glucoside (ZEN14Glc) since this glycoside cannot be detected during routine 
analysis, but is hydrolysed during digestion. In 2011, the International Life Science Institute 
(ILSI) has adapted the definition whereby masked mycotoxins are defined as mycotoxin 
derivatives that are undetectable by conventional analytical techniques because their 
structure has been changed in the plant. However, there are also other substances derived 
from mycotoxins, which are likewise not detectable in routine analysis, but which are 
primarily not produced by plants (Berthiller et al., 2013). In order to avoid misunderstanding 
the term modified mycotoxins has been introduced by Rychlik et al. (2014) and includes all 
potential mycotoxin derivatives. Table 1.1. gives an overview of this systematic definition of 
the modified mycotoxins. The emphasis of this definition has been placed on the processes 
whereby these modified toxins can be generated in order to encompass all possible forms. 
As some molecules can be generated in different ways, some compounds belong to more 
than one category (Rychlik et al., 2014).  
 
According to this definition the term ‘free or unmodified’ mycotoxins describes the basic 
mycotoxin structures formed as toxic secondary metabolites by various fungi in well-known 
biosynthetic pathways. Examples are OTA, AFB1, FB1, ZEN and DON. Matrix-associated 
mycotoxins are used for mycotoxins, which (1) form either complexes with matrix 
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compounds or are physically dissolved or trapped or (2) are covalently bound to matrix 
components or a combination of both effects. Examples for covalently bound forms of 
mycotoxins are fumonisins bound to starch or proteins (Seefelder et al., 2003; Shier, 2000). 
Recently also the covalent binding of OTA to polysaccharides via the carboxylic acid group of 
OTA during the roasting of coffee has been shown by Bittner et al. (2013). Also, DON-
oligosaccharides have been described recently (Zachariasova et al., 2012). 
 
 
Table 1.1. Systematic definition of modified mycotoxins (Rychlik et al., 2014) 
Free or unmodified 
mycotoxins 
   
Matrix-associated 
mycotoxins 
 
- Complexes, physically  
   dissolved or trapped 
  
- Covalently bound   
Modified  
mycotoxins 
- Biologically modified - Functionalised (Phase I metabolites)  
- Conjugated by (Phase II metabolites) - Plants 
- Animals 
- Fungi 
- Differently modified  
- Chemically modified - Thermally formed  
- Non-thermally formed  
 
 
The term ‘modified mycotoxins’ describes any modification of the basic chemical structure 
of mycotoxins either by chemical or biological modifications. Biologically modified 
mycotoxins include any functionalisation during phase I metabolism, for example AFB1-exo-
8,9-epoxide, which is the aflatoxin metabolite that reacts covalently with deoxyribonucleic 
acid (DNA) to form adducts responsible for toxic effects (see chapter 2). Furthermore, 
mycotoxin conjugates such as phase II metabolites are also defined as biologically modified. 
These include (1) conjugation reactions by plants such as the formation of deoxynivalenol-3-
glucoside (DON3Glc) or ZEN14Glc, which are defined as masked mycotoxins (Berthiller et al., 
2013); (2) conjugation reactions by animals such as the formation of deoxynivalenol-3-
glucuronide (DON3GlcA) or deoxynivalenol-15-glucuronide (DON15GlcA) (Uhlig et al., 2013; 
Welsch and Humpf, 2012); and (3) conjugations by fungi as for example the formation of 
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zearalenone-14-sulphate (ZEN14S) (Plasencia and Mirocha, 1991). All other biological 
modifications are summarised under the term ‘differently modified’ and include for example 
deepoxy-deoxynivalenol (DOM-1) as an intestinal metabolite of DON, which is formed by the 
microbiota of animals and humans (Eriksen et al., 2003; Gratz et al., 2013).  
 
Chemically modified mycotoxins are currently the largest group of modified mycotoxins and 
can be classified as ‘thermally and non-thermally formed’. Thermal modifications occur 
during food and feed processing including baking, roasting, frying, or extruding. Thermal 
degradation products have been described for several mycotoxins such as fumonisins 
(Humpf and Voss, 2004; Seefelder et al., 2001), DON (Bretz et al., 2006), OTA (Cramer et al., 
2008) and T-2 (Beyer et al., 2009). Examples for non-thermal modifications of mycotoxins 
are the formation of hydrolysed fumonisins, degradation reactions induced by UV light for 
OTA and CIT (Schmidt-Heydt et al., 2012) or DON sulphonate generated by treatment of 
contaminated feed with sodium bisulfite (Danicke et al., 2010). 
 
1.3 LEGISLATION 
 
Since it is unrealistic to avoid the formation of mycotoxins, governmental regulatory 
agencies survey for the occurrence of mycotoxins in food and feed and establish regulatory 
limits to control the mycotoxin exposure of the population. The establishment of the 
maximum limits is based on epidemiological data and extrapolations from animal models, 
taking into account the different uncertainties associated with both types of analysis. 
Various factors affect the promulgation of mycotoxin limits and regulations such as the 
availability of toxicological and exposure data, the knowledge of mycotoxin distribution 
within commodities or the availability of analytical methods for mycotoxins (Van Egmond et 
al., 2007).  
 
Current EU legislation includes maximum levels of aflatoxins, fumonisins, OTA, DON and ZEN 
in foods (1881/2006/EC), AFB1 in feed (2002/32/EC) and guidance values for fumonisins, OTA, 
DON and ZEN in products intended for animal feeding (2006/576/EC). Recently, indicative 
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values regarding the occurrence of T-2 and HT-2 toxin (HT-2) in cereals and cereal products 
in food and feed (2013/165/EC) were established and in 2014 maximum levels of the 
contaminant citrinin in food supplements based on rice fermented with red yeast Monascus 
purpureus were included (212/2014/EC). Table 1.2. and table 1.3. give an overview of the 
maximum limits and guidance levels for mycotoxins in food and feed established by the 
European Commission. Regulations concerning sampling and analytical methods for the 
official control of mycotoxins in food and feed were established as well (401/2006/EC; 
2002/657/EC). Current legislations are increasing based on scientific opinions of 
authoritative bodies such as the European Food Safety Authority (EFSA). At the same time, 
different European organisations and programs such as the Scientific Cooperation on 
Questions relating to Food (SCOOP), the Rapid Alert System for Food and Feed (RASFF), the 
creation of an EU Community Reference Laboratory for Mycotoxins (CRL) and the European 
Standardisation Committee (CEN) have a direct and indirect influence on the development of 
mycotoxin regulations. Until today no maximum limits or guidance values for mycotoxins in 
urine are available. 
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u
m
a
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n
su
m
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o
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u
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a
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n
g
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d
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n
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o
o
d
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u
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it
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 t
h
e
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e
p
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o
n
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u
n
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n
u
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p
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n
u
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o
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re
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b
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 p
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 b
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 b
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n
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 b
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 c
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 b
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 c
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 p
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 p
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 c
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 c
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b
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 p
is
ta
ch
io
s 
a
n
d
 a
p
ri
co
t 
k
e
rn
e
ls
, 
in
te
n
d
e
d
 f
o
r 
d
ir
e
ct
 h
u
m
a
n
 c
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 c
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 l
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 p
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 c
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 c
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 c
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d
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u
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n
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 b
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u
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 c
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 m
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 m
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 m
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 m
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 p
ro
d
u
ct
s 
—
 
—
 
0
.0
5
0
 
1
4
 
F
o
ll
o
w
in
g
 s
p
e
ci
e
s 
o
f 
sp
ic
e
s:
 C
a
p
si
cu
m
 s
p
p
. 
(d
ri
e
d
 f
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 c
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 c
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p
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 b
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ra
g
ra
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u
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e
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g
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g
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g
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u
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u
m
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o
n
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e
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 m
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 o
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5
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 c
e
re
a
l-
b
a
se
d
 f
o
o
d
s 
a
n
d
 b
a
b
y 
fo
o
d
s 
fo
r 
in
fa
n
ts
 a
n
d
 y
o
u
n
g
 c
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0
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d
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k
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 m
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p
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 b
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 f
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 r
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p
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 m
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 m
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 b
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 c
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 c
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 c
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 b
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 c
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 p
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 p
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 c
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 c
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M
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n
g
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ra
ct
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n
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o
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m
a
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 p
a
rt
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 m
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 c
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 m
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 p
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 m
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 c
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 c
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 c
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 c
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 c
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 c
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 f
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ra
is
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 b
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 c
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 c
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 c
o
ff
e
e
 (
in
st
a
n
t 
co
ff
e
e
) 
 
1
0
.0
 
 
6
 
W
in
e
 (
in
cl
u
d
in
g
 s
p
a
rk
li
n
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 l
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e
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 o
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 d
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 c
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p
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 c
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 c
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 c
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 c
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e
re
o
f,
 i
n
cl
u
d
in
g
 w
h
it
e
 a
n
d
 b
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ra
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 l
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CHAPTER 2  
HEALTH EFFECTS OF MYCOTOXINS 
 
 
Toxicokinetics studies the changes of mycotoxin concentrations in the body in function of 
time. These changes depend on the degree and the speed of four processes namely 
absorption, distribution, metabolism and excretion (ADME). The ADME processes are 
presented in figure 2.1.  
 
 
 
 
 
 
 
Figure 2.1. Toxicokinetic processes 
 
Most of the toxicokinetic studies for mycotoxins are performed in animal studies. In contrast, 
the knowledge of these processes for mycotoxins in humans is until today not well 
developed. Absorption of mycotoxins occurs mainly through the gastro-intestinal tract via 
ingested contaminated food. The exposure of mycotoxins through residues in animal derived 
food is much lower in comparison with exposure through vegetable food. Absorption 
through inhalation or skin contact occurs to a lesser extent. Moreover, an enterohepatic 
cycle exists for mycotoxins, i.e. recycling via biliary excretion (Boonen et al., 2012; Pfeiffer et 
al., 2011; Ringot et al., 2006). After absorption mycotoxins are distributed over the body 
through the blood where mycotoxins can bind to red blood cells or to plasma proteins like 
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albumin. Studies on the distribution of mycotoxins to tissues is rather scarce. Most of the 
mycotoxins have a plasma half-life of 24 to 48 hours, except for OTA. Elimination of 
mycotoxins occurs through biotransformation and excretion. Biotransformation is the 
chemical transition to a more hydrophilic metabolite before excretion takes place. Enzymes 
of the liver play an important role in biotransformation. Biotransformation can lead to a 
bioactivation or detoxification. Excretion is the removal of the component out of the body. 
The main routes of mycotoxin excretion are via the kidneys (urine) or via the bile (faeces). 
Excretion through air, via salivary-, perspiratory- and mammary glands is negligible 
(Malekinejad et al., 2005). Toxicokinetic parameters differ within and between humans. For 
example children, adults and elderly show differences in absorption, metabolisation and 
excretion. Also the influence of several diseases or the intake of drugs on the kinetics of 
mycotoxins needs more research. 
 
Toxicodynamics studies the interaction of a mycotoxin with biological targets and their 
downstream biological effects. For most of the mycotoxins the liver and the kidney are the 
target organs (Bennett and Klich, 2003; Fodor et al., 2008). Furthermore, mycotoxins can be 
carcinogenic, immunosuppressive, teratogenic or mutagenic.  
 
This chapter gives an overview of the toxicokinetics, with main focus on biotransformation 
and excretion, and toxicological effects of each mycotoxin in humans. When no data are 
available in humans, results from studies performed in pigs are mentioned because of the 
given anatomical and physiological similarity of the gastro-intestinal tract, liver and kidneys.  
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2.1 AFLATOXINS 
 
2.1.1 Toxicokinetics 
 
AFB1 absorption, distribution and elimination is rapid. AFB1 is well absorbed and 
accumulates in liver where it is extensively metabolised. Aflatoxins are metabolised in the 
body by a variety of routes that can lead to either activation, i.e. the formation of aflatoxin 
8,9-epoxide that binds to proteins and DNA or detoxification, being the formation of 
metabolites that are more easily excreted. There are four metabolic pathways of AFB1: (1) O-
dealkylation to aflatoxin P1 (AFP1), (2) ketoreduction to aflatoxicol (AFL), (3) epoxidation to 
AFB1-8,9-epoxide and (4) hydroxylation to AFM1, aflatoxin Q1 (AFQ1) and aflatoxin B2a (AFB2a). 
Cytochrome P450 enzymes (CYP), more precisely CYP3A4 and 1A2 in humans, convert 
aflatoxins to the reactive 8,9-epoxide form (Eaton and Gallagher, 1994; Gallagher et al., 
1994). CYP1A2 metabolises AFB1 to AFB1-endo-8,9-epoxide which is less toxic considering 
that it cannot bind nucleic acids and can be excreted under different forms. Both the exo- 
and endo-epoxides can undergo rapid non-enzymatic hydrolysis to AFB1-8,9-dihydrodiol, 
reacting with the aminogroup of lysine in serum albumin. Detoxification of the epoxide can 
also occur enzymatically via conjugation to glutathione, mediated by glutathione-S-
transferase found in the cytosol and microsomes, leading to the excretion of aflatoxin 
(Calderone and Cihlar, 2002; Raj et al., 1986). Figure 2.2. gives an overview of the different 
biotransformation pathways of AFB1. The parent compound is excreted in faeces and 
unbound water-soluble metabolites are excreted in urine (Riley et al., 2011). 
 
Literature data has shown that AFB1 can be transferred through human placenta and 
metabolised by local enzymes. The placenta contains low levels of CYP enzymes, with 
variations depending on the stage of placental development. Furthermore, AFM1 is a 
frequent metabolite in milk of exposed lactating animals, including in human breast milk 
after maternal exposure to dietary AFB1 (Wild and Gong, 2010). 
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Figure 2.2. Metabolic pathway of AFB1 in animals and human leading to reactive metabolites and biomarkers. 
(1A2: CYP1A2; 3A4: CYP3A4; 3A5: CYP3A5; GST: glutathione S-transferase; AFAR: aflatoxin aldehyde 
reductase; Aflatoxin-S-G: aflatoxin-glutathione conjugate)(Wild and Turner, 2002). 
 
2.1.2 Toxicity 
 
The diseases caused by aflatoxin consumption are called aflatoxicoses. Acute aflatoxicosis 
results in death whereas chronic aflatoxicosis results in cancer and immune suppression 
(Hsieh, 1988). The liver is the primary target organ and the magnitude of the response is 
influenced by several factors such as age, sex or the presence of other mycotoxins and 
pharmacologically active substances (Newberne and Butler, 1969). Aflatoxins are classified 
as group 1 carcinogenic for humans by the International Agency of Research on Cancer 
(IARC). AFB1 and AFG1 possess an unsaturated bond at the 8,9 position on the terminal furan 
ring and subsequent studies demonstrated that epoxidation at this position and the 
formation of mutagenic DNA adducts is the key initiating step in the carcinogenesis of 
aflatoxins (Groopman and Kensler, 2005; Wild and Turner, 2002). AFB2 and AFG2 are 
Aflatoxin-endo 8,9-epoxide 
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relatively non-toxic because of the lack of the unsaturated bond at the 8,9 position unless 
they are first metabolically oxidized to AFB1 and AFG1 in vivo. Mechanistically, it is known 
that the reactive aflatoxin epoxide binds to the N7 position of guanines in DNA. Moreover, 
AFB1-DNA adducts can result in guanine-cytosine to thymine-adenine transversions (Cullen 
and Newberne, 1994).  
 
Because of the differences in aflatoxin susceptibility in laboratory animals, it has been 
difficult to extrapolate the possible effects of aflatoxin to humans. It has been hypothesised 
that kwashiorkor, a severe malnutrition disease, may be a form of pediatric aflatoxicosis 
(Hendrickse, 1997). Further early speculations that aflatoxin might be involved in Reye’s 
syndrome, an encephalopathy, and fatty degeneration of the viscera in children and 
adolescents have not been substantiated (Hayes, 1980). Furthermore, aflatoxins cause 
growth suppression in animals and limited evidence suggests that such effects may also 
occur in humans. Gong et al. (2004) performed a study in Benin whereby a strong negative 
correlation was found between aflatoxin-albumin adducts and height of children. Turner et 
al. (2007) demonstrated a strong effect of maternal aflatoxin exposure during pregnancy on 
the growth in the first year of life in Gambia. The underlying mechanisms of the effect of 
aflatoxin exposure during infancy on faltering growth remains unclear. Exposure to 
aflatoxins in the diet is considered as an important risk factor for the development of 
primary hepatocellular carcinoma, particularly in individuals already exposed to hepatitis B. 
In different animal studies aflatoxin induced a high incidence of hepatocellular carcinoma, 
suspecting that this agent could contribute to human cancer (Eaton and Gallagher, 1994; 
Gallagher et al., 1994). In classical epidemiology, several studies have linked liver cancer 
incidence to estimated aflatoxin consumption in the diet. For example, Peers and Linsell 
(1973) and Van Rensburg et al. (1985) performed studies in Kenya and Mozambique 
whereby a positive correlation was found between dietary aflatoxin intake and 
hepatocellular carcinoma. The results of these studies have not been entirely consistent, and 
quantification of lifetime individual exposure to aflatoxin is extremely difficult.  
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2.2 CITRININ 
 
2.2.1 Toxicokinetics 
 
Specific toxicokinetic studies with oral administration are not available for CIT. CIT is 
eliminated predominantly by renal excretion, as described in a study with radiolabelled CIT 
by Reddy et al. (1982) in which approximately 75 % of the intraperitoneal dose was 
recovered in urine of rats. Approximately 74 % of the radioactivity appeared in the urine in 
the first 24 h, with only 1.7 % and 1.4 % in the urine at 48 h and 72 h, respectively. Sandor et 
al. (1991) described a subacute toxicity study with OTA and CIT in pigs. In this limited study, 
groups of three animals were given CIT, OTA or both compounds and compared with a group 
of five control animals. The authors concluded that CIT is more rapidly eliminated than OTA. 
No toxicokinetic studies have been conducted in humans. 
 
2.2.2 Toxicity 
 
Studies on the mechanism of CIT toxicity were performed exclusively in vitro. Inhibition of 
ribonucleic acid (RNA) and DNA synthesis by CIT has been reported in different mammalian 
cell lines including kidney cells (Wasternack and Weisser, 1992; Yoneyama and Sharma, 
1987). Only few studies on adverse effects of CIT in pigs could be identified. At present, no 
effect has been reported from pigs given 20 μg/kg body weight (BW) per day (Sandor et al., 
1991). EFSA considered this intake value as a no observed adverse effect level (NOAEL), 
which is consistent with the results from a subchronic study in rodents (Lee et al., 2010). 
Available animal studies revealed that CIT induces renal adenomas and chromosome 
abnormalities. However as no lifetime exposure studies are available, no conclusion can be 
drawn regarding the potential carcinogenicity of CIT. In repeated dose toxicity studies, the 
kidney was identified as the principal target organ for CIT and significant species differences 
in the susceptibility to CIT have been observed. Studies of the immunotoxicity of CIT are 
rather incomplete, often non-specific and do not allow a conclusive evaluation. In vitro and 
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in vivo studies provided clear evidence for reproductive toxicity and teratogenic and 
embryotoxic effects of CIT. Furthermore, CIT has multiple effects on mitochondrial function, 
impairing mitochondrial respiration with subsequent loss in cellular adenosine triphosphate 
(ATP) levels. Whether alteration of mitochondrial function is a primary or contributing 
mechanism to cell death by CIT remains to be clarified (Segvic et al., 2012).  
 
2.3 FUMONISINS 
 
2.3.1 Toxicokinetics 
 
Toxicokinetic studies indicated that FB1 is poorly absorbed by the gastro-intestinal tract and 
rapidly cleared from the plasma in laboratory animals. FB1 doesn’t extensively accumulate in 
tissues although low levels of FB1 were found in the liver and kidney (Norred et al., 1996; 
Shephard et al., 1995). Following intragastric dosing, FB1 appeared in the blood after 30 min 
and was mainly eliminated in the faeces within 72 hours. Less than 1 % was excreted in urine 
and an enterohepatic recirculation contributes to a longer half-life of the mycotoxin. Only a 
few data have been reported in literature about the metabolism of FB1 (Marasas et al., 2001). 
An in vivo experiment performed by Fodor et al. (2008) in pigs showed the transformation of 
FB1 by intestinal microbiota to partially hydrolysed FB1 and hydrolysed FB1 (HFB1 or 
aminopentol). HFB1 was less potent than FB1 as an inhibitor of ceramide synthase in vitro but 
its derivative appeared to be tenfold more toxic than FB1 .  
 
2.3.2 Toxicity 
 
The chemical structure of FB1 is similar to sphingosine (So) and sphinganine (Sa), the 
backbones of sphingolipids (SL). As result of this similarity, FB1 inhibits the enzyme ceramide 
synthase, a key enzyme in the SL metabolism. The primary amine function appears necessary 
for its biological activity. Inhibition of ceramide synthase results in a decrease of de novo 
synthesis of ceramide and SL (Dragan et al., 2001). The blocking of this pathway by FB1 leads 
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to an increase in free sphinganine and to a lesser extent in sphingosine (figure 2.3.). SL’s are 
important constituents of cell membranes and by impairing SL metabolism FB1 alters the 
membrane functions. One affected function is the folate receptor function which possibly 
causes the inhibition of folate intake and possible neural tube defects (NTD). Different 
animal studies showed that the brain SL metabolism was disturbed after FB1 dosing, which 
might suggest that the disturbed SL metabolism is responsible for the FB1 toxicity (Kwon et 
al., 1997). Furthermore, FB1 blocks the mitochondrial respiration by inhibiting the 
mitochondrial electron transport chain. This leads to depolarisation of the membrane, 
reactive oxidative species (ROS) over-production and calcium deregulation, resulting in cell 
death (Domijan, 2012). 
 
 
Figure 2.3. Sphingolipid metabolism showing the inhibition of ceramide synthase  by fumonisins and the 
changed concentrations of other compounds caused by this inhibition (Merrill et al., 2001) 
 
FB1 is a neurodegenerative mycotoxin and ingestion of FB1 contaminated feed has been 
associated with pulmonary oedema in pigs (Harrison et al., 1990) and equine 
leukoencephalomalacia (ELEM), a brain disorder in horses (Marasas, 1996). In animal models, 
FB1 was shown to be neurotoxic, carcinogenic and immunotoxic. The most affected organs 
are the kidneys and the liver (Gelderblom et al., 1991). In certain regions of the world, where 
maize is a staple food, higher incidence of oesophageal cancer was connected with dietary 
exposure to FB1. For this reason, IARC classified FB1 in group 2B as a possible carcinogen to 
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humans. However, epidemiological data are still lacking and a direct causal role has not been 
established.  
 
2.4 OCHRATOXINS 
 
2.4.1 Toxicokinetics 
 
OTA is passively absorbed in the gastro-intestinal tract and has a high affinity for plasma 
proteins. Also reabsorption of OTA from the intestine, enterohepatic recirculation and 
reabsorption in the kidney proximal and distal tubulus favor its accumulation in the body 
(Dahlmann et al., 1998).  In humans, OTA has a serum half-life of about 35 days (Schlatter et 
al., 1996). Different studies in human showed that the OTA concentration in foetal serum 
was higher than the maternal one, indicating an active placental transfer (Miraglia et al., 
1998). Furthermore, several studies reported OTA levels in breast milk suggesting OTA 
transfer to milk (Munoz et al., 2013). Biotransformation of OTA has not been elucidated in 
detail. The major metabolic pathway is the hydrolysis into a less toxic compound, ochratoxin 
α (OTα) mainly through the intestinal microflora. In addition, a small percentage of absorbed 
OTA is hydroxylated into 4-hydroxy-OTA (4-OH-OTA) through phase I detoxification reactions 
whereby two epimers are formed (Marquardt and Frohlich, 1992). The 4(R)-OH-OTA epimer 
is mainly formed by human CYP3A4, CYP1A2 and CYP2C9 and is less toxic than OTA. In some 
animal species also 10-hydroxy-OTA (10-OH-OTA) production has been described. OTC is a 
naturally occurring toxin and can be converted to OTA in the body. Additionally OTA can be 
conjugated with glucuronic acid and sulphates during phase II metabolisation. The absence 
of these conjugates in several studies remains an open question (Gross-Steinmeyer et al., 
2002). In all species faecal and urinary excretions play important roles in plasma clearance of 
OTA. Renal excretion occurs through tubular elimination and is carried out by several 
transporter proteins. Both OTA and its metabolite OTα are excreted in the faeces due to the 
biliary excretion (Ringot et al., 2006).   
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2.4.2 Toxicity 
 
Various studies in animals and humans have associated OTA with endemic porcine 
nephropathy and Balkan endemic nephropathy (Pfohl-Leszkowicz and Manderville, 2007). 
Kidneys are the main target organ for OTA and its immunosuppressive properties result in 
higher susceptibility to infections. Furthermore, OTA is teratogenic and IARC classified OTA 
in group 2b as a possible carcinogen for human. OTA inhibits protein synthesis by competing 
with phenylalanine (Creppy et al., 1995). Conflicting data exists on the genotoxicity of OTA 
and in particular its mode of action. Increasing evidence suggests that the various genetics 
effects seen in in vitro and in vivo studies are compatible with the hypothesis of DNA 
damage induced by oxidative stress rather than indicating direct interaction (adduct 
formation) of OTA with cellular DNA. Furthermore, chemical analysis failed to identify 
specific DNA adducts of OTA or its metabolites (EFSA, 2006).  
 
2.5 TRICHOTHECENES 
 
2.5.1 Toxicokinetics 
 
In general, the available information on toxicokinetics of T-2 is incomplete for each animal 
species. Up to now, five biotransformation pathways of T-2 toxin, involving hydrolysis, 
hydroxylation, de-epoxidation, glucuronidation and acetylations, have been described in 
different biological systems, resulting in a large number of different metabolites. The main 
metabolic pathway in all species is via a rapid deacetylation in C-4, resulting in the formation 
of HT-2. This reaction is catalysed by a non-specific carboxyesterase found in blood plasma 
and in several tissues, primarily in the liver. Depending on the metabolic pathway, HT-2 can 
be further deacetylated, hydroxylated or conjugated. The metabolism of T-2 in human skin 
revealed three major metabolites namely HT-2, T-2 triol and T-2 tetraol. The minor 
metabolic pathway (hydroxylation of T-2) is an activation reaction since 3-hydroxy-T-2 was 
found to be more toxic (Wu et al., 2010).  
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The toxicokinetics of DON have been established in rats and pigs, but are not yet fully 
understood for humans. DON is detectable in serum in high amounts immediately after 
ingestion, but is rapidly cleared from the blood stream. The main fraction is excreted by 
urine and a smaller part is eliminated in faeces (Turner, 2010). DON has a short half-life 
because of its fast excretion (4 to 8h). Generally, DON is rapidly metabolised and does not 
accumulate in tissues (Pestka, 2010). Recently, the first in vivo case study providing 
detailed information about the human metabolism of DON in one volunteer was published 
(Warth et al., 2013a). DON, DON3GlcA and DON15GlcA were detected in human urine 
whereby 68 % of the ingested dose was excreted in urine. None of these toxins were 
detectable after 24 hours after exposure, which suggests a rapid metabolism of DON. The 
excretion of DON and its glucuronides occurred within 3-5 hours after consumption of 
lunch. The glucuronidation ratio was calculated to be 76 % with DON15GlcA as main DON 
metabolite found in human urine samples (73 %). Besides DON3GlcA and DON15GlcA, a 
third DON metabolite was found with large similarities to the spectra of the other DON 
glucuronides, suggesting the presence of deoxynivalenol-7-glucuronide (Maul et al., 2012).   
 
2.5.2 Toxicity 
 
Toxicodynamic studies have demonstrated that the trichothecenes function as inhibitor of 
eukaryotic protein synthesis. Trichothecenes bind to the 60S-ribosomal subunit and interact 
with peptidyltransferase (figure 2.4.). This interaction leads to the inhibition of the 
polypeptide chain initiation (T-2) or elongation-termination (DON) (Pestka and Smolinski, 
2005). The toxic properties of trichothecenes reside in the common 12,13 epoxide group 
that allows them to inhibit protein synthesis. T-2 is the strongest protein synthesis inhibitor, 
whereas DON is less potent. Addition of an acetyl chain (see 2.7.) can further influence  its 
inhibitory potential (Ueno, 1983).  
 
The toxic effects are known to involve ribotoxic stress responses. Trichothecenes activate 
mitogen-activated protein kinases (MAPKs) of a signaling cascade that regulates cell survival 
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in response to stress and induces rapid apoptosis (Moon and Pestka, 2003; Pestka et al., 
2004).  
 
 
Figure 2.4. Mechanism involved in trichothecene induced toxicity (Pestka, 2007). Trichothecenes function as 
inhibitor of eukaryotic protein synthesis as they bind to the 60S-ribosomal subunit and interact with 
peptidyltransferase. Trichothecenes activate mitogen-activated protein kinases of a signaling cascade that 
regulates cell survival in response to stress and induces rapid apoptosis. 
 
The acute toxicity of trichothecenes results in nausea, vomiting, diarrhea and gastro-enteric 
distress. Cells of the immune system are central targets of the trichothecenes. 
Pathophysiologically, DON has been linked to anorexia, growth retardation and 
immunotoxicity in animal models. It is yet to be established whether DON is related to 
certain chronic conditions in humans, such as colitis or inflammatory bowel syndrome. 
However, so far it has been shown that DON has no carcinogenic effects, neither in animals 
nor humans. IARC has listed trichothecenes as group 3 non-carcinogenic. T-2 is the most 
acutely toxic among the trichothecenes. For most of the metabolites of T-2 toxin, no or very 
limited toxicological information is available. Nevertheless, the de-epoxidation is considered 
to be an important detoxification step. Furthermore, T-2 and HT-2 are able to penetrate 
across the blood brain-barrier in vivo (Weidner et al., 2013). 
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2.6 ZEARALENONE 
 
2.6.1 Toxicokinetics 
 
Recently, the first in vivo case study providing detailed information about the human 
metabolism of ZEN in one volunteer was published (Warth et al., 2013a). 9.4 % of ZEN was 
excreted in the urine after the ingestion of naturally contaminated food. Furthermore, 
zearalenone-14-glucuronide (ZEN14GlcA) was detected in urine samples 3-10 hours after 
lunch, which indicates a rapid formation and excretion of ZEN14GlcA. ZEN is metabolised by 
3α- and 3β-hydroxysteroid dehydrogenase into α- and β-zearalenol (α- and β-ZEL), 
respectively. β-ZEL has lower affinity for the estrogen receptor, whereas α-ZEL has higher 
binding affinity compared to ZEN. The metabolisation to β-ZEL can be seen as a 
detoxification step, whereas the metabolisation to α-ZEL leads to bioactivation (Malekinejad 
et al., 2005). Also phase II metabolisation reactions take place whereby ZEN and its 
metabolites are conjugated with glucuronic acid, catalysed by uridine diphosphate 
glucuronyl transferases. Glucuronidation enhances the water solubility of compounds, thus 
enhancing renal elimination (Pfeiffer et al., 2010). On the other hand, enterohepatic 
recycling occurs by biliary excretion followed by an intestinal deconjugation and 
reabsorption, which has been demonstrated for ZEN (Biehl et al., 1993).  
 
2.6.2 Toxicity 
 
ZEN exerts its toxic action by passively crossing the cell membrane and competitively binding 
to the estrogen-receptor. The formed ligand-receptor-complex is transferred to the nucleus 
where it binds to specific nuclear receptors, and generates estrogenic responses via gene 
activation (figure 2.5.) (Metzler et al., 2010; Riley and Norred, 1996).  
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Figure 2.5. Mechanism involved in ZEN induced toxicity in animals (Riley and Norred, 1996). ZEN exerts its 
toxic action by passively crossing the cell membrane and competitively binding to the estrogen-receptor. The 
formed ligand-receptor-complex is transferred to the nucleus where it binds to specific nuclear receptors, and 
generates estrogenic responses via gene activation.  
 
ZEN is involved in reproductive disorders in animals and hyperestrogenic conditions in 
humans.  The estrogenic effects on humans and animals are a result of interaction of the 
toxin or its metabolites with the estrogen receptor. They are structurally similar to 17β-
estradiol and therefore act as estrogenic agonists. Human studies have shown that ZEN may 
be involved in the etiology of breast cancer (Yu et al., 2005) and may affect humans in the 
pre-pubertal stage (Massart and Saggese, 2010). Besides its endocrine disrupting and 
anabolic effects, ZEN was reported to induce hepatocellular lesions in animal models, which 
are likely to lead to the development of local adenomas. The central nervous system consists 
of other α- and β-estrogen receptors and effects on this level are reported as ZEN is able to 
pass the blood-brain barrier, still the ovaria and uterus are more sensitive. IARC has listed 
ZEN as group 3 non-carcinogenic. 
 
2.7 MODIFIED MYCOTOXINS 
 
Potential exposure to modified mycotoxins due to their presence in food and feed raises 
concern that modified mycotoxins may pose an additional risk to human and animal health. 
Conjugated and matrix-associated mycotoxins may be cleaved by the gut microflora to the 
parent compound and thus add to the systemic exposure and toxicity of the free mycotoxin. 
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Therefore it is critical to assess the bioavailability and toxic potential of modified mycotoxins 
(Rychlik et al., 2014).  
 
Only a few in vivo data on ADME processes and toxicity of modified mycotoxins are yet 
available. The best studied examples so far involve derivatives of DON and ZEN namely 
DON3Glc, 3-acetyl-deoxynivalenol (3ADON), 15-acetyl-deoxynivalenol (15ADON) and 
ZEN14Glc. In vitro studies on the comparative toxicity of DON and its acetylated derivatives 
demonstrate that 15ADON is more toxic and 3ADON is less toxic compared to DON. DON3Glc 
may be hydrolysed to DON in the gastro-intestinal tract and thus may contribute to the total 
dietary exposure to DON (Nagl et al., 2014). Therefore, it may be concluded that data on the 
toxic potential of DON3Glc using cellular or molecular endpoints in vitro such as inhibition of 
protein synthesis may not be accurate predictors of systemic toxicity of DON3Glc in animals 
or humans. DON is nearly completely modified to DOM-1 in cattle by rumen micro-
organisms prior to systemic absorption. This modification occurs also in pigs, but to a lesser 
extent as most of the DON is already absorbed before reaching the intestinal segment where 
DON is converted to DOM-1. Therefore, in DON-exposed cattle, mostly DOM-1 is detectable 
in blood while in pigs the majority is in the form of free DON (Daenicke and Brezina, 2013). 
Similarly to DON3Glc, glycosylation of the estrogenic mycotoxin ZEN by plants to its 
derivative ZEN14Glc has been shown to prevent binding to estrogen receptors 
(Poppenberger et al., 2006). It is important for human and animal health risk assessment to 
consider that ZEN14Glc may be cleaved during digestion and release its active parent 
compound as demonstrated in pigs (Gareis et al., 1990). These examples emphasize the need 
for toxicokinetic and toxicity data on modified mycotoxins to allow human and animal health 
risk assessment (Rychlik et al., 2014).  
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CHAPTER 3  
MYCOTOXIN EXPOSURE ASSESSMENT:  
FRAMEWORK AND METHODOLOGICAL ASPECTS 
 
 
3.1 THE GENERAL FRAMEWORK OF RISK ASSESSMENT 
 
Food contains a wide range of substances which are either desired (nutrients, additives) or 
undesired, such as mycotoxins. As a result, both nutritional and food safety issues are 
important determinants of public health and therefore deserve continued attention from 
scientific and from policy perspective. A very important aspect within mycotoxin research is 
risk assessment. According to the International Programme on Chemical Safety (IPCS, 2004) 
health risk is defined as the probability of an adverse effect in an organism, system or 
population caused under specified circumstances by exposure to an agent. The use of a 
structured risk analysis process facilitates decision-making in the area of food safety. Risk 
analysis has been defined by the Codex Alimentarius Commission as a process consisting of 
three components: risk assessment, risk management and risk communication. Within risk 
analysis, the functional separation between risk assessors and risk managers is essential to 
ensure scientific objectivity of the risk assessment process (FAO/WHO, 2008).  
 
Risk assessment of food chemicals can be generally described as characterising the potential 
hazards and the associated risks to life and health resulting from exposure of humans to 
chemicals present in food over a specified period. It provides a mechanism for the structured 
review of information relevant to estimating health outcomes in relation to exposure to 
chemicals present in food and forms the scientific basis for the risk management executed 
by governments. Risk assessment is defined as a four-step process (figure 3.1.). Within this 
chapter the different steps will be explained with a direct link to the scope of this doctoral 
thesis. 
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Figure 3.1. Four-step process of risk assessment 
 
Hazard identification is the first of four steps in risk assessment. The purpose of food 
chemical hazard identification is to evaluate the weight of evidence for adverse health 
effects, based on assessment of all available data on toxicity and mode of action. It is 
designed to address two questions namely the nature of the health hazard that an agent 
may pose and the circumstances under which the hazard may be expressed. The nature of 
the toxicity or adverse health effect and the affected target organs are identified using in 
vitro and in vivo toxicity tests. The hazard identification concerns the determination of the 
different compounds to be included in the analysis of the risks related to mycotoxins.  
Although a very wide range of mycotoxins may accumulate in the food chain, it was decided 
to limit this study to the most abundant mycotoxins with emphasis on those with available 
human biomarkers of exposure. For this reason aflatoxins, CIT, fumonisins, ochratoxins, 
trichothecenes and ZEN were included in this study whereby dietary intake is the main route 
of exposure (see chapter 1).  
 
Hazard characterisation describes the relationship between the dose/exposure and the 
incidence of the adverse health effect (dose-response relationships) and includes all 
toxicokinetic and toxicodynamic data concerning mycotoxins (see chapter 2). In cases where 
the toxic effect is assumed to have a threshold, hazard characterisation usually results in the 
establishment of health-based guidance values such as a tolerable weekly intake (TWI) or a 
tolerable daily intake (TDI). This establishment is based on the determination of a NOAEL in 
toxicological studies and the application of an uncertainty factor. The uncertainty factor 
means that the lowest NOAEL in animal studies is divided by 100, 10 for extrapolation from 
animals to humans and 10 for variation between individuals, to arrive at a tolerable intake 
Hazard 
identification 
Hazard 
characterisation 
Exposure  
assessment 
Risk  
characterisation 
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level. In cases where the data are inadequate, higher safety factors are used (FAO, 2003). 
Table 3.1. gives an overview of the health-based guidance levels  for mycotoxins in humans. 
  
Table 3.1. Health-based guidance levels for mycotoxins in humans 
Mycotoxin Health-based guidance level Reference 
Aflatoxins No TDI since carcinogenic effects  
Fumonisins  Group TDI = 2 μg/kg BW/day FAO/WHO (2012) 
Ochratoxin A TWI = 0.12 µg/kg BW/week EFSA (2006) 
Deoxynivalenol + acetylated forms Group TDI = 1 μg/kg BW/day FAO/WHO (2010) 
T-2 + HT-2 toxin Group TDI = 0.1 μg/kg BW/day EFSA (2011a) 
Zearalenone TDI = 0.25 μg/kg BW/day EFSA (2011b) 
 
 
The largest part of the work executed in this PhD-thesis is related to the exposure 
assessment. The latter has been defined as the qualitative and/or quantitative evaluation of 
the likely intake of chemical agents via food as well as exposure from other sources if 
relevant (FAO/WHO 2008). In the case of food chemicals, dietary intake is usually estimated 
by models combining data on food consumption with concentration data measured in foods 
and food groups and the likelihood of consumers eating large amounts of the foods in 
question (high consumers) and of the chemical being present in these foods at high levels. 
Usually a range of intake or exposure estimates will be provided and estimates may be 
broken down by subgroup of the population (e.g. children, adults). Because of some 
uncertainties related to this approach, the direct measurement of biomarkers of exposure 
has become an added value in evaluating exposure. It is the only available tool that 
integrates exposures from all sources (Choi et al., 2015). Furthermore, the individual 
variation in ADME processes is integrated when using biomarkers, whereby a more accurate 
assessment of exposure can be performed at the individual level. The experimental part of 
this PhD-thesis focuses on the exposure assessment of mycotoxins for the Belgian 
population using biomarker analysis (see chapter 5-7). 
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The latter step, risk characterisation, integrates the information collected in the preceding 
three steps. The information from the intake or exposure assessment and the hazard 
characterisation is integrated into advice suitable for decision-making in risk management. 
Risk characterisation provides estimates of the potential risk to human health under 
different scenarios. It can be qualitative or quantitative. It should include a clear explanation 
of any uncertainties resulting from gaps in the science base and information on susceptible 
subpopulations. Finally the risk of mycotoxin exposure of the Belgian population was 
evaluated within this study. Based on the urinary mycotoxin concentrations, the dietary 
intake was estimated and was compared to TDI’s (see chapter 6). The results of this PhD- 
thesis can help policy makers to get a better picture of the mycotoxin exposure of the 
Belgian population and to develop a strategy to tackle the potential public health problem 
related to mycotoxin exposure.  
 
Risk assessment is followed by risk management, which is the process, distinct from risk 
assessment, of weighing policy alternatives, in consultation with all interested parties, 
considering risk assessment and other factors relevant for the health protection of 
consumers and if needed selecting appropriate prevention and control options. Risk 
managers are responsible for the final decisions on establishing maximum limits for 
contaminants such as mycotoxins.  
 
Additionally risk communication is defined as the interactive exchange of information and 
opinions throughout the risk analysis process concerning risk, risk-related factors and risk 
perceptions, among risk assessors, risk managers, consumers, industry, the academic 
community and other interested parties, including the explanation of risk assessment 
findings and the basis of risk management decisions (FAO/WHO 2008). 
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3.2 BIOMARKERS OF EXPOSURE 
 
Biomarkers are measurable biochemical or molecular indicators of either exposure 
(biomarkers of exposure) or biological response (biomarkers of effect) to a mycotoxin that 
can be specifically linked to the proximate cause (Baldwin et al., 2011). Mechanism-based 
biomarkers often include changes in the level of specific proteins, cellular metabolites, or 
gene expression resulting from specific alterations in metabolic or signaling pathways, stress 
responses, cell proliferation, or cell death. Typical biomarkers of exposure are the parent 
toxins themselves, protein or DNA adducts and major phase I and II metabolites (e.g. 
glucuronide conjugates). These compounds can be detected in easily-accessed biological 
fluids such as urine and are related to the actual intake of the toxin through contaminated 
food. Ideally, such a marker should reflect the toxicokinetics, transformation and fate of the 
assessed contaminant in the body. Regardless of the type, all biomarkers should be specific, 
sensitive and as less invasive as possible (Crews et al., 2001). Sensitivity is related to the 
possibility of detection of the assessed contaminant or its metabolites when found in low 
amounts either in food or biological samples; the limit of detection (LOD) is an issue, 
considering that significant biological effects that may occur in humans following long term 
exposure to such low levels. Specificity is the certainty of associating the marker only to the 
exposed compound and not to other unrelated compounds. The most common parameters 
in quantifying exposure or effect are available from urine, serum and milk, although for 
some of the toxins there are a few other biological matrices that can provide us with 
important information, like faeces, nails or hair. Within this PhD thesis only biomarkers of 
exposure will be described with emphasis on urinary biomarkers. 
 
3.2.1 Biomarkers for exposure to aflatoxins 
 
By the late 1980’s, two major biomarkers of aflatoxin exposure were developed: the urinary 
DNA adduct AFB1-N7-Guanine and the serum albumin adduct. The urinary DNA adduct 
reflects recent exposure as excretion occurs over 24-48 hours, whereas the albumin adduct 
reflects long-term exposure (2-3 months). Wild et al. (1986) showed that there was a 
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correlation between DNA adducts and serum albumin adducts in rats fed with AFB1. Both 
biomarkers were further validated through population studies whereby a dose-dependent 
relationship between aflatoxin exposure and excretion in human urine and blood was shown 
(Egner et al., 2006; Groopman et al., 1993; Wild et al., 1992). Furthermore, correlations 
between ingestion of AFB1 and excretion of AFM1 in urine were observed in different 
populations (Zhu et al., 1987).  
 
3.2.2 Biomarkers for exposure to citrinin 
 
Data on biomonitoring of CIT are scarce because of the lack of suitable methods for human 
specimens. Recently, a few studies have been conducted whereby CIT and its metabolite 
dihydrocitrinone (HO-CIT) were analysed in human blood and urine (Blaszkewicz et al., 2013; 
Degen et al., 2014). Further research is needed to investigate if HO-CIT is a possible 
biomarker for CIT exposure in human and animals. 
 
3.2.3 Biomarkers for exposure to fumonisins 
 
FB1 is detectable in urine, serum and faeces and it has been proposed as a biomarker of 
exposure, despite the fact that the detectable concentrations in all physiological fluids are 
quite low, approaching the LOD of the method used (Shephard et al., 2007). Moreover, the 
detection window of the toxin is very narrow, so only recent exposure can be quantified. 
Nevertheless, the correlation of this marker to fumonisin exposure needs to be further 
investigated in humans.  
 
The disruption of sphingolipid metabolism results in an increase of sphinganine (Sa) levels 
and of sphinganine to sphingosine (So) ratio. Although older studies promote usage of Sa as 
biomarker of exposure to fumonisins, recently it has been suggested that Sa is not reliable in 
relation to the fumonisin exposure levels. The Sa:So ratio is a useful marker in animals, but it 
failed to correlate human exposure to fumonisins in a satisfactory way, probably because 
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the exposure in human population is generally low. Moreover, the normal variation of Sa:So 
ratio is considerably large and fluctuates over time regardless of the levels of exposure to 
the mycotoxin. Several studies conducted by the same author in Europe, Africa and South- 
America also show that the Sa:So ratio in urine and plasma may not be a relevant marker.  
Despite this, considering that most of the studies in literature promote these two 
parameters as valid in evaluating fumonisins effect, they cannot yet be excluded as 
biomarkers (Shephard et al., 2007; Van der Westhuizen et al., 2010).   
 
Sewram et al. (2003) showed for the first time that FB1, FB2 and FB3 can accumulate in 
human hair as a result of contaminated maize consumption. Hair analysis is relevant in 
measuring exposure to fumonisins regardless of source or intake profile, in terms of low, 
medium or high exposure. However, there is a big inter-individual variability, due to ethnicity, 
age, gender and other factors.  
 
3.2.4 Biomarkers for exposure to ochratoxins 
 
OTA is ubiquitous in human blood (serum and plasma), being an indicator of continuous 
exposure to this mycotoxin (Munoz et al., 2010). Despite the fact that urinary levels of OTA 
are considerably lower than in blood, following a study in the UK, urine was found to be a 
better marker of OTA intake (Gilbert et al., 2001). Around 50 % of the ingested OTA is 
excreted in urine, the rest being metabolites or conjugates of the toxin. The major metabolic 
pathway of OTA is represented by its hydrolysis to OTα. It is the only metabolite found so far 
in humans (Munoz et al., 2010).  
 
OTA has been detected in various concentrations in breast milk of mothers in Europe. 
Nevertheless, up to the present time there is no correlation between OTA levels in breast 
milk compared to serum, suggesting that the transfer from blood to milk is not yet fully 
understood (Munoz et al., 2014; Munoz et al., 2013).  Data regarding the ability of OTA or its 
metabolites to form adducts with nucleic acids is controversial. Certain studies have shown 
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formation of DNA adducts in humans (Pfohl-Leszkowicz et al., 2007). Until recently, studies 
suggested that OTA is poorly metabolised and does not form reactive intermediates capable 
of interacting with DNA (Mally et al., 2004).  
 
3.2.5 Biomarkers for exposure to trichothecenes 
 
Turner et al. (2008c) established that there is a quantitative correlation between urinary 
DON and the exposure to this mycotoxin. In human studies, the same authors identified 
urinary DON as being a reliable biomarker of exposure in UK and French populations (Turner 
et al., 2010a; Turner et al., 2010b). Moreover, the levels of DON in urine significantly 
correlated to the amount of contaminated cereals ingested one day prior to the urine 
collection.  
 
So far, it is certain that there are two major metabolites of DON in mammals: DON 
glucuronide (DON3GlcA and DON15GlcA) and DOM-1 (Gratz et al., 2013; Warth et al., 2013a). 
DOM-1 is most likely generated by the intestinal microbiota of mammals and in particular in 
cattle where more than 95 % of DON is metabolised to DOM-1. Moreover, deepoxy-
deoxynivalenol-glucuronide (DOMGlcA) is also ubiquitous in cows (Goyarts and Danicke, 
2006; Pestka and Smolinski, 2005), being found in higher amounts than the parent 
compound. It is yet to be proven that DOM-1 is a relevant biomarker of exposure for DON in 
humans. Literature data suggests that DOM-1 is not a major metabolite in humans, 
considering that it is not found in all individuals (Gratz et al., 2013). The major metabolite of 
DON found in urine, both for animals and humans, are DON-glucuronides. DON-glucuronides 
have been previously found in urine and serum of pigs and recent data showed that in 
humans, about 91 % of the total urinary DON is represented by its glucuronide metabolites 
(Turner et al., 2010b). For T-2 and HT-2 no correlations between intake and urinary levels 
have been described yet. 
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3.2.6 Biomarkers for exposure to zearalenone 
 
Malekinejad et al. (2006) showed that the biotransformation of ZEN is species dependent 
and there is a small amount of data related to human metabolism of this compound. It is 
generally known that there are two main metabolites occurring in animals and humans: α-
ZEL and β-ZEL. Both metabolites undergo two further biotransformation pathways and can 
be conjugated with glucuronic acid. Glucuronidation is an important pathway in 
detoxification and elimination of ZEN, and in some species (e.g. pigs) ZEN undergoes total 
glucuronidation (Malekinejad et al., 2006). Most data regarding the presence of ZEN in 
physiological fluids and compartments are available as toxicokinetic studies in animal models. 
In rats and pigs, it was isolated from serum, urine, bile and faeces following oral and 
intravenous administration. In humans, ZEN and its metabolites α-ZEL and β-ZEL have been 
isolated from naturally contaminated urine samples (Solfrizzo et al., 2014), but there is no 
data correlating their presence in urine with the extent of ZEN exposure. Very often, ZEN 
derivates in urine were found to be conjugated with glucuronic acid, so it would be viable to 
evaluate glucuronides in humans as possible biomarkers for ZEN.  
 
3.3 BIOMONITORING IN MYCOTOXIN RESEARCH: STATE OF THE ART 
 
Biomarker research for human exposure assessment to mycotoxins started in the late 1980’s 
when extensive studies on the carcinogenic aflatoxins were conducted (Wild and Turner, 
2002). They have been essential for the establishment of the role of aflatoxins in human 
disease through better estimates of exposure, expanded knowledge of the mechanisms of 
disease pathogenesis, and as tools for implementing and evaluating preventive interventions. 
Later in the 1990’s work on OTA (Duarte et al., 2011) and the fumonisins (Shephard et al., 
2007) was conducted. The first biomarker research on DON was initiated by Meky et al. 
(2003).  
 
As a result of the latest generation of high performance liquid chromatography tandem mass 
spectrometry (LC-MS/MS) instruments, a clear trend towards the development and 
[CHAPTER 3] METHODOLOGICAL ASPECTS OF EXPOSURE ASSESSMENT 
 
 
| 45  
application of multi-analyte methods in mycotoxin biomarker research can be observed. 
Purification of the analytes is often achieved by using extensive sample cleanup approaches 
(Ediage et al., 2012). However, the latest studies have also successfully applied the so-called 
dilute and shoot approach by omitting any cleanup step (Warth et al., 2012b). This chapter 
provides a short overview of published (multi)biomarker methods, discusses challenges 
associated with biomarker analysis and summarises human exposure assessment studies 
performed within the past decade. 
 
3.3.1 Biomarker methods and their application in exposure assessment studies 
 
Single biomarker methods 
 
The first biomarker research on DON was initiated by Meky et al. (2003). This biomarker 
research investigated the metabolism of DON in rats as a basis to establish methodology for 
a candidate biomarker of human exposure and this methodology was tested on urine 
samples from a potentially highly exposed population. Urine samples were collected from 
female inhabitants of Linxian County, a high risk region for oesophageal cancer and Gejiu, a 
low risk region in China. DON was detected in all 15 samples following β-glucuronidase 
treatment and immunoaffinity column (IAC) enrichment with the identity of DON being 
confirmed by mass spectrometry (LOD 4 ng/mL). The mean levels of DON from the 
suspected high and low exposure regions of China were 37 ng/mL (14-94 ng/mL) and 12 
ng/mL (4-18 ng/mL), respectively. Furthermore, Turner et al. (2008a) have developed a LC-
MS/MS method with IAC enrichment and inclusion of 13C-DON as an internal standard. The 
developed method was tested in a pilot survey performed in the UK whereby 25 healthy 
adults participated. Urine samples were analysed for DON following β-glucuronidase 
treatment (LOQ 0.6 ng/mL). This intervention study involved 2 days of normal diet and 4 
days of a wheat-restricted diet. During consumption of the normal diet, all individuals had 
detectable urinary levels of DON, while fewer samples were positive (36 %) during the 
intervention. The geometric mean level during normal diet was 7.2 ng/mg creatinine (4.9-
10.5 ng/mg creatinine). This is 11-fold higher than the 0.6 ng/mg creatinine (0.4-0.9 ng/mg 
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creatinine) during the intervention. This study found a significantly association between 
urinary DON and cereal intake. Additionally, Turner et al. (2010a) refined the previous 
method by adding DOM-1 to the method (LOD 0.05 ng/mL). The refined method was applied 
to a pilot survey of male French farmers (n= 76, aged 23-74) whereby DON was detected in 
75/76 urine samples (0.5-28.8 ng/mL) and DOM-1 in 26/76 samples (0.2-2.8 ng/mL). It was 
the first exposure biomarker survey for DON in a French population, and the first 
demonstration of urinary DOM-1 in humans. Hepworth et al. (2012) conducted a study in a 
subset of pregnant women from Bradford, UK. Women aged 16–44 years (n= 85) provided a 
urine sample for DON analysis in the last trimester of pregnancy, and completed a food 
frequency questionnaire (FFQ). The urinary DON biomarker was detected in all measured 
samples (0.5-116.7 ng/mg creatinine). Levels were higher in women classified as South Asian 
in origin compared with non-South Asians. This was the first biomarker demonstration of 
DON exposure in pregnant women. Srey et al. (2014) assessed DON exposure in children 
from three geographic locations within Tanzania, over three time points in 1 year using the 
same LC-MS/MS method. A total of 166 children aged 6–14 months were studied at maize 
harvest and followed up twice at 6-month intervals. On two consecutive days, morning urine 
was collected from each child and urinary DON was measured using an LC-MS/MS method, 
with and without β-glucuronidase hydrolysis in order to assess free DON and its 
glucuronides. Overall, urinary DON increased significantly along with the three visits. 51 % of 
the urine samples collected during the first visit were contaminated with DON (mean 1.1 
ng/mL; 0.8-1.4 ng/mL), while 70 % was contaminated during visit two (mean 2.3 ng/mL; 1.7-
3.2 ng/mL). 80 % of the samples was positive for DON at the third sample collection (mean 
5.7 ng/mL; 2.34.1-7.9 ng/mL).  
 
Warth et al. (2011) developed a LC-MS/MS method allowing quantification of both DON 
(LOD-LOQ 6-20 ng/mL) and DON3GlcA (LOD-LOQ 3-10 ng/mL) by a simple dilute and shoot 
approach without the need for any cleanup. The applicability of the method was 
demonstrated through the analysis of urine samples obtained from a volunteer during a 
regular and cereal-restricted diet. All four urine samples obtained from the cereal-restricted 
diet showed neither DON3GlcA nor DON contamination. In contrast, both samples analysed 
after normal diet including cereal products were positive for the glucuronide conjugate (31 
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and 32 µg/L). Furthermore, Warth et al. (2012a) performed a pilot survey to investigate the 
level of DON exposure in Austrian adults (n= 27) by measurements of DON (LOD-LOQ 4-13 
ng/mL) and its glucuronides in first morning urine. The average concentration of total DON 
(22 % free + 96 % glucuronides) was estimated to be 20.4 µg/L (max. 63 µg/L) whereby one 
third of the volunteers exceeded the TDI when consuming regular diet. DON-glucuronides 
were directly quantified by LC-MS/MS and the results were compared with indirect 
quantification after enzymatic hydrolysis and confirmed the suitability of the direct method. 
DON15GlcA (LOD-LOQ 3.2-10.6 ng/mL) could be identified as a major DON metabolite in 
human urine based on the analysis of these samples. About 25 % of total DON glucuronides 
were derived from DON3GlcA (LOD-LOQ 6-20 ng/mL). Recently, Gratz et al. (2014) 
conducted a pilot study in the UK, whereby spot urine samples were collected in two 
consecutive years from 15 volunteers following their habitual diet. Urinary DON was 
analysed by LC-MS/MS after hydrolysis and IAC enrichment to estimate 24-h DON excretion 
and daily dietary DON intake. DON (LOD 0.10 ng/mL) was detectable in all urine samples 
with an average excretion of 10.08 µg/24h in year one, which significantly increased in year 
2 (24.84 µg/24h). The TDI for DON was exceeded in 13 % of occasions in year 2 (mean intake 
518.64 ng/kg BW/day) and none in year 1 (mean intake 195.94 ng/kg BW/day) suggesting 
that DON exposure varies annually.  
 
The aim of the study performed by Munoz et al. (2010) was to develop a method that allows 
analysis of OTA (LOQ-LOQ 0.02-0.05 ng/mL) and its detoxication product OTα (LOQ-LOQ 
0.02-0.05 ng/mL) in urine and in blood plasma. The method involves enzymatic hydrolysis of 
conjugates, liquid–liquid extraction, and analysis of sample extracts by high performance 
liquid chromatography with fluorescence detection (HPLC-FD). Application of the validated 
method in a pilot study with 13 volunteers from Germany revealed the presence of OTA 
(0.02-0.13 ng/mL) and OTα (0.05-4.7 ng/mL) in all samples. Duarte et al. (2010) evaluated 
the exposure of the Portuguese population (n= 155) to OTA (LOQ 0.008 ng/mL). Morning 
urine samples were collected during the Winter of 2007, from each of five geographically 
distinct Portuguese locations and subjected to extraction by IAC before HPLC-FD analysis. 
92.2 % of the urine samples were positive for OTA (mean 0.018 ng/mL; max. 0.069 ng/mL). 
Duarte et al. (2012) examined factors related to OTA exposure in the adult population of 
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Portugal over a one-year period. Anthropometric measures, season of the year and region 
were the selected factors correlated with OTA exposure biomarker. Urine samples from 95 
inhabitants (50 women and 45 men) from six Portuguese main geographical areas were 
analysed using a HPLC–FD method (Pena et al., 2006) and included IAC enrichment (LOD-
LOQ 0.008-0.024 ng/mL). Exposure to OTA proved to markedly increase in winter (87.4 %; 
mean 0.022 ng/mL), and gender differences were observed only in summer (81.1 %; mean 
0.016 ng/mL), which might be related to different dietary patterns not only between seasons, 
but also between genders. Furthermore, Ali et al. (2014) collected 64 blood samples from 
healthy university students (32 female, 32 male) in Bangladesh for biomarker analysis. OTA 
(LOD-LOQ 0.05-10 ng/mL) and its metabolite OTα (LOD-LOQ 0.05-10 ng/mL) were 
determined in the plasma samples by a validated method using HPLC-FD analysis. After 
liquid–liquid extraction, OTA was detected in all plasma samples (0.20-6.63 ng/mL) and OTα 
was detected in 95 % of the samples (0.10-0.79 ng/mL). The OTA mean level in plasma of 
males and females were not significantly different. Statistical analysis of food consumption 
data for the participants, provided in a FFQ, did not reveal a significant association between 
OTA level in plasma and their intake of typical staple foods (rice, wheat, maize and lentil). 
The dietary intake of OTA calculated on the basis of plasma concentration in Bangladeshi 
students was lower than the TWI of OTA. Additionally, Munoz et al. (2014) conducted a 
longitudinally designed study in Chilean mother–child pairs (n= 21) with parallel collection of 
maternal blood, milk and infant urine samples over a period of 6 months. Validated LC-
MS/MS methods were applied to determine OTA concentrations in all 134 biological samples 
(LOD-LOQ urine 30-50 ng/L). OTA was detected in almost all maternal blood plasma at 
concentrations ranging between 72 and 639 ng/L. Infants’ exposure was calculated as daily 
intake from OTA levels in breast milk taking into account milk consumption and body weight. 
The statistical analysis showed a good correlation (r= 0.57) between OTA intake and infant 
urine concentrations (30-433 ng/L) during breastfeeding period and thereby confirms that 
urinary OTA analysis in infants is a valid biomarker of exposure.  
 
Van der Westhuizen et al. (2011a) conducted the first study in South Africa assessing 
fumonisin exposure by evaluating Sa, So and Sa:So ratios in plasma and urine of participants 
as possible biomarkers of exposure. After HPLC-FD analysis of 41 plasma and 62 urine 
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samples no association was found between sphingoid base levels in the plasma and urine 
(1.9-40 ng/mL) and individual fumonisin exposure. 
 
Blaszkewicz et al. (2013) developed a sensitive method for the analysis of CIT and HO-CIT in 
human blood and urine to investigate human exposure. Clean-up of blood plasma by protein 
precipitation followed by LC–MS/MS analysis allowed robust detection of CIT. For urine, 
sample clean-up by an IAC proved to be clearly superior to solid phase extraction (SPE) prior 
to LC–MS/MS analysis (LOQ-LOQ 0.02-0.05 ng/mL). The newly developed method was 
applied in a small pilot study. CIT was present in all plasma samples (n=8) at concentrations 
ranging from 0.16 to 0.79 ng/mL. CIT was detected in 8/10 urines (0.05-0.2 ng/mL) and HO-
CIT (LOD-LOQ 0.05-010 ng/mL) was present in 5/10 urine samples (0.15-1.12 ng/mL). Ali et al. 
(2014) applied this method to investigate CIT exposure in 50 German adults (n= 27 females 
and n= 23 males). CIT and HO-CIT were detected in 82 % and 84 % of all urine samples, at 
concentrations ranging from 0.02 to 0.08 ng/mL for CIT, and 0.05 to 0.51 ng/mL for HO-CIT. 
Except for higher urinary CIT levels in males, differences between subgroups were not 
significant.  
 
Multi-biomarker methods 
 
The first method described for the determination of various mycotoxin biomarkers in human 
urine was developed by Ahn et al. (2010). To achieve sufficient sensitivity and selectivity, 
AFM1, OTA, FB1 and FB2 were concentrated using three separate IAC’s and OTα was 
extracted using liquid-liquid extraction. Also two other published multi-biomarker methods 
used the selectivity of antibodies by applying a multi-IAC column which comprises antibodies 
specific for aflatoxins, OTA, fumonisins, DON, ZEN, T-2 and HT-2 (Rubert et al., 2011; 
Solfrizzo et al., 2011a). Solfrizzo et al. (2011a) developed a LC-MS/MS method for 
simultaneous determination of AFM1, OTA, DON, DOM-1, α-ZEL, β-ZEL and FB1 in human and 
pig urine. Urine samples were purified and concentrated by a double cleanup approach, 
using a multi-toxin IAC and an Oasis® HLB column. Ten samples of human urine were 
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collected from healthy Italian volunteers (five male and five female) with a range of ages 
(26–87 years old). All samples were analysed twice, i.e. without and with enzymatic 
digestion with β-glucuronidase before sample cleanup, with increasing concentrations after 
digestion. Most of the samples tested positive for DON and/or OTA whereas no other 
biomarkers were detected.  Co-occurrence of OTA and DON (70 %) in human urine was for 
the first time reported. The developed method was further used to detect levels of DON, 
DOM-1, AFM1, FB1, ZEN, α-ZEL, β-ZEL and OTA in urine samples of 52 volunteers resident in 
Apulia region in Southern Italy (Solfrizzo et al., 2014). The presence of ZEN + ZEL’s, OTA, DON, 
FB1 and AFM1 was detected in 100 % (0.120 ng/mL + 0.176 ng/mL), 100 % (2.129 ng/mL), 96 % 
(67.36 ng/mL), 56 % (0.352 ng/mL) and 6 % (0.146 ng/mL) of the samples, respectively. 
Urinary biomarker concentrations were used to estimate human exposure to multiple 
mycotoxins. For OTA and DON, 94 % (0.053 µg/kg BW/day) and 40 % (1.03 µg/kg BW/day) of 
the volunteers exceeded TDI for these mycotoxins. A simple and rapid method for 
quantitative determination of DON, T-2, HT-2, ZEN, OTA, aflatoxins and fumonisins in urine 
was developed by (Rubert et al., 2011). For clean-up and extraction, the mixture was loaded 
on a IAC and samples were analysed using an ion trap mass spectrometer for detection. In a 
pilot study in the UK with 27 volunteers, OTA (11.1 %), DON (33.3 %) and AFG2 (3.7 %) were 
detected (Rubert et al., 2011). A LC-MS/MS method developed by Ediage et al. (2013) covers 
seven mycotoxins and several important conjugation and breakdown products (in total 18 
analytes). Sample cleanup was optimised in a progressive procedure where urine samples 
were extracted using liquid-liquid extraction followed by SPE. More detailed information 
about this method can be found in section 5.3.1. This study was conducted to investigate 
mycotoxin exposure in children (n= 220, aged 1.5–4.5 years) from high mycotoxin 
contamination regions of Cameroon and to examine the association between the mycotoxin 
levels (in total 18 analytes) and several socio-demographic factors and anthropometric 
characteristics. DON (0.1-77 ng/mL), OTA (0.04-2.4 ng/mL), AFM1 (0.06-4.7 ng/mL), FB1 (0.06-
48 ng/mL), ZEN (0.65-5 ng/mL), α-ZEL (0.26-1.3 ng/mL) and β-ZEL were detected in 
respectively 17 %, 32 %, 14 %, 11 %, 4 %, 8% and 4 % of the urine samples. There were 
significant differences in the mean contamination levels of OTA and β-ZEL between the two 
agro-ecological zones investigated. Likewise significant differences were observed in the 
mean levels of AFM1 across the weaning categories of these children. The mean 
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concentration of AFM1 detected in the urine of the partially breastfed children was 
significantly higher than those of the fully weaned children. Meanwhile, the mean 
concentrations of DON and FB1 detected in the urine of the male children was significantly 
different from the levels detected in the urine of female children. In this study, there was no 
association between the different malnutrition categories (stunted, wasting and 
underweight) and the mycotoxin concentrations detected in the urine of these children.  
 
Warth et al. (2012b) developed an LC-MS/MS method for the quantitative measurement of 
15 mycotoxins and key metabolites in human urine. DON, DON3GlcA, DON15GlcA, DOM-1, 
nivalenol (NIV), T-2, HT-2, ZEN, ZEN14GlcA, α- and β-ZEL, FB1, FB2, OTA and AFM1 were 
determined without the need for any cleanup using a rapid and simple dilute and shoot 
approach. The applicability of the method was demonstrated by the analysis of urine 
samples obtained from Cameroon (n= 175). In naturally contaminated urine samples up to 
six biomarkers of exposure (AFM1, DON, DON15GlcA, NIV, FB1 and OTA) were detected 
simultaneously. The same LC-MS/MS method was used by Sarkanj et al. (2013) in a pilot 
survey conducted in pregnant women (n=40) from eastern Croatia. DON and its glucuronides 
were detected in 98 % of the studied samples, while OTA was found in 10 % (<4 ng/mL) of 
the samples. DON exposure was primarily reflected by the presence of DON15GlcA with a 
mean concentration of 120 ng/mL (1-1237.7 ng/mL), while free DON was detected with a 
mean concentration of 18.3 ng/mL (9-275 ng/mL). Several highly contaminated urine 
samples contained a third DON conjugate, tentatively identified as deoxynivalenol-7-
glucuronide. 48 % (0.1-33.1 µg/kg BW/day) of subjects were estimated to exceed the TDI of 
DON. Furthermore, Ezekiel et al. (2014) performed a pilot, cross-sectional, correlational 
study in eight rural communities in northern Nigeria to investigate mycotoxin exposures in 
120 volunteers (19 children, 20 adolescents and 81 adults) using the same LC–MS/MS based 
multi-biomarker approach. First morning urine samples were analysed and urinary 
biomarker levels were correlated with mycotoxin levels in foods consumed the day before 
urine collection. A total of eight analytes were detected in 50.8 % of the studied urine 
samples, with OTA (28 %; mean 0.2 ng/mL), AFM1 (14 %; mean 0.3 ng/mL) and FB1 (13 %; 
mean 4.6 ng/mL) being the most frequently occurring biomarkers of exposure. A pilot study 
was conducted whereby 60 first-morning urine samples were collected from healthy 
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volunteers who live in the Bangkok metropolitan area and surrounding provinces 
(Pathumthani, Nonthaburi, Samutprakarn and Samutsakorn). Urine samples were analysed 
using the same ‘dilute and shoot’ approach. AFM1, OTA, DON3GlcA and DON15GlcA were 
detected in respectively 5 % (mean 0.16 ng/mL), 1.7 % (0.33 ng/mL), 5 % (mean 4.3 ng/mL) 
and 11 % (mean 8.1 ng/mL) of the individuals. The maximum concentrations were used to 
estimate the daily intake confirming that none of the individuals exceeded the TDI of DON or 
OTA. This was the first multi-mycotoxin biomarker study performed in South-East Asia 
(Warth et al., 2014). Abia et al. (2013) studied the frequency and level of exposure to 
multiple mycotoxins in human urine from Cameroonian adults. 175 urine samples (83 % 
from HIV-positive individuals) and a FFQ were collected from Cameroonians, and analysed 
for 15 mycotoxins and relevant metabolites using the LC-MS/MS method developed by 
Warth et al. (2012b). In total, eleven analytes were detected individually or in combinations 
in 110/175 (63 %) samples including the biomarkers AFM1 (0.17-1.38 ng/mL), FB1 (1.7-14.8 
ng/mL), FB2 (1.7 ng/mL), NIV (10-22 ng/mL), ZEN (1.3-1.42 ng/mL), ZEN14GlcA (3.3-31 ng/mL), 
OTA (0.17-1.87 ng/mL), DON (13 ng/mL), DON15GlcA (20-66.2 ng/mL) and DON3GlcA (20-
22.8 ng/mL).  
 
Huybrechts et al. (2014) developed a LC-MS/MS method for the detection of 32 biomarkers 
in urine samples without any sample clean-up. More detailed information about the method 
can be found in section 5.3.2. The method was pilot-tested in 32 Belgian volunteers whereby 
all urine samples contained DON15GlcA (3.1-420.1 ng/mL). Also DON3GlcA (0.5-55.4 ng/mL) 
and DOMGlcA (0.5-16.4 ng/mL) were present in, respectively, 90 and 25 % of the samples, 
while DON (0.5-3.1 ng/mL) was detected in 60 % of the samples, in lower concentrations. 
OTA ( 3-32.6 pg/mL) was detected in 70 % of the samples. CIT and HO-CIT were detected in 
59 % (3-117 pg/mL) and 66 % (30-208.5 pg/mL) of the samples.  
 
Rodriguez-Carrasco et al. (2014a) performed a pilot survey whereby human urine samples 
were analysed for presence of 15 mycotoxins and some of their metabolites using a novel 
urinary multi-mycotoxin gas chromatography tandem mass spectrometry (GC–MS/MS) 
method following salting-out liquid–liquid extraction. Fifty-four urine samples from children 
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and adults in Valencia were analysed for the presence of urinary mycotoxins. Four out of 15 
mycotoxins were detected. 37 samples showed quantifiable values of mycotoxins. DON 
(mean-max. 25.1-84.5 µg/g creatinine) was the most frequently detected mycotoxin (68.5 %) 
whereby 8.1 % of total subjects were estimated to exceed the TDI. NIV (mean 15.13 µg/g 
creatinine) was found in 13 % of the samples, HT-2 (mean 13.67 µg/g creatinine) in 7.4 % 
and DOM-1 (mean 2.75 µg/g creatinine) in 3.7 %.  
 
Shephard et al. (2013) applied novel urinary multi-mycotoxin LC–MS/MS methods to 
determine multiple exposure biomarkers in the high oesophageal cancer region, Transkei, 
South Africa. Fifty-three female participants donated part of their maize-based evening meal 
and first void morning urine, which was analysed both with sample clean-up (single and 
multi-biomarker) and by a ‘dilute-and-shoot’ multi-biomarker method. A single biomarker 
method detected FB1 (LOD-LOQ 0.01-0.02 ng/mL) in 87 % of the urine samples with a 
concentration between 0.01-1.3 ng/mL (Gong et al., 2008). After hydrolysis with β-
glucuronidase was DON (LOD-LOQ 0.25-0.50 ng/mL) detected in 100 % of the samples 
between 0.3-99.2 ng/mL (Gong et al., 2008; Turner et al., 2008a). The multi-biomarker 
‘dilute-and-shoot’ method indicated the presence of DON15GlcA in 55 % of the samples with 
a maximum concentration of 47 ng/mL  (Warth et al., 2012b). A multi-biomarker method 
with β-glucuronidase and IAC clean-up determined ZEN (100 %; 0.012-3.15 ng/mL), FB1 (96 %; 
0.04-4.94 ng/mL), α-ZEL (92 %; 0.009-3.72 ng/mL), DON (87 %; 0.45-53.4 ng/mL), β-ZEL (75 %; 
0.016-5.94 ng/mL) and OTA (98 %; 0.002-0.432 ng/mL) (Solfrizzo et al., 2011b). All the LOD 
and LOQ values of the different multi-biomarker methods mentioned, are summarized in 
table 3.2. 
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Table 3.2. LOD and LOQ values of the different multi-biomarker methods 
LOD/LOQ 
ng/mL 
Ahn et al. 
(2010) 
Solfrizzo et al. 
(2011a) 
Rubert et al. 
(2011) 
Warth et al. 
(2012b) 
Rodriguez-Carrasco et al. 
(2014a) 
AFM1  0.003/0.010 0.020/- - 0.05/0.17 - 
OTA 0.001/0.004 0.006/- 0.5/1.5 0.05/0.17 - 
FB1 0.007/0.022 0.010/- 5/15 0.5/1.7 - 
FB2 0.003/0.010 - 4/15 0.5/1.7 - 
OTα 0.045/0.135 - - - - 
DON - 1.5/- 10/35 4/13 0.12/0.25 
DON3GlcA - - - 6/20 - 
DON15GlcA - - - 6/20 - 
DOM-1 - 9.9/- - 10/33 0.25/0.50 
NIV - - - 3/10 0.5/1 
ZEN - 0.007/- 3/10 0.4/1.3 3/6 
ZEN14GlcA - - - 1/3.3 - 
α-ZEL - 0.030/- - 0.5/1.7 1/2 
β-ZEL - 0.054/- - 0.5/1.7 2/4 
T-2 - - 2/6 2/6.7 0.5/1 
HT-2 - - 3/10 20/67 1/2 
AFB1 - - 0.5/1.5 - - 
AFB2 - - 0.4/1.2 - - 
AFG1 - - 0.4/1.2 - - 
AFG2 - - 0.8/2 - - 
3ADON - - - - 0.25/0.50 
FusX - - - - 2/4 
DAS - - - - 1/2 
NEO - - - - 0.25/0.50 
ZAN - - - - 4/8 
α-ZAL - - - - 4/8 
β-ZAL - - - - 4/8 
*ZAN = zearalanone ; α-ZAL = α-zearalanol; β-ZAL = β-zearalanol 
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3.3.2 Analytical challenges 
 
A major challenge in mycotoxin biomarker research is the extremely low analyte 
concentrations present in biological fluids following dietary exposure. Hence, appropriate 
sample preparation protocols are crucial to obtain acceptable LOD’s. This is, however, 
challenging due to the chemical diversity of analytes typically included in multi-biomarker 
methods. This issue becomes even more complex once polar conjugates such as 
glucuronides are included as they are frequently lost during common cleanup approaches 
such as SPE or IAC procedures (Warth et al., 2012b). The great advantage of the methods 
using IAC’s for cleanup is the specific retention of the target compounds only. Thereby, 
potentially interfering matrix compounds are removed efficiently. The major disadvantage is 
that no conjugates or other biomarkers of interest can be included in a method. 
Furthermore, enzymatic hydrolysis should be performed to include conjugates, and the 
overall procedure is time-consuming and costly and requires a labor-intensive sample 
preparation. This is in contrast to the dilute and shoot approach, where a urine sample is 
centrifuged, diluted, and analysed without further pretreatment. However, to overcome 
matrix effects and interfering matrix peaks, variables such as eluents and the 
chromatographic gradient need to be carefully optimised (Warth et al., 2012b; Warth et al., 
2013b).  
 
Ediage et al. (2012) investigated different procedures including dilute and shoot, dilute, 
evaporate, and shoot, liquid–liquid extraction, and concluded that the approaches based on 
sample dilution yielded unfeasibly high LOD’s and significant signal enhancement for ZEN 
and FB1. Furthermore, Warth et al. (2012b) tested various SPE cartridges during method 
development of the dilute and shoot method. Most of these SPE columns failed to retain the 
polar glucuronide conjugates, with the exception of the Oasis® HLB. When using dilute and 
shoot methods, co-eluting matrix components can influence the accuracy of quantitative 
methods through ion suppression or enhancement. These matrix effects can be controlled 
by using matrix-matched calibration (Solfrizzo et al., 2011a), inclusion of 13C labelled internal 
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standards (Ahn et al., 2010; Turner et al., 2008b), or correction of results with the apparent 
recovery (Huybrechts et al., 2014).  
 
In the past, most biomarker methods focused on parent mycotoxins rather than on 
conjugated forms as no (certified) calibrants are commercially available for these 
metabolites. Furthermore, direct quantification of mycotoxin conjugates without enzymatic 
hydrolysis is commonly used as incomplete hydrolysis and the time-consuming sample 
preparation can be overcome. An important quality control measure is the use of certified 
reference materials including well-characterized calibrants to monitor the performance of a 
certain method. However, for mycotoxin biomarkers, there is no matrix reference material 
available that would make it possible to assess the measurement performance in the 
analysis of biologically important matrices. This is critical especially in view of the complex 
biological matrices and makes efforts such as a recent interlaboratory comparison (Solfrizzo 
et al., 2013) even more important to ensure analytical accuracy.  
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CHAPTER 4  
AIMS AND RESEARCH QUESTIONS 
 
 
Mycotoxins are secondary metabolites produced by fungi. These naturally occurring toxins 
are important harmful food contaminants responsible for health effects such as cancer, 
nephrotoxicity, hepatotoxicity or immunosuppression. More than 400 mycotoxins have been 
reported, whereby AFB1, DON, FB1, OTA, ZEN and T-2 form the greatest risk for human and 
animal health (Riley and Pestka, 2005). People can be exposed through consumption of 
contaminated food, dermal contact and inhalation of toxins present in dust and air (Miraglia 
et al., 2009). Although the European Commission established maximum levels for these 
mycotoxins in food and feed, mycotoxins form a worldwide problem (1881/2006/EC; 
2006/576/EC). 
 
In order to study the impact of mycotoxins on the public health, it is important to assess 
human exposure. The assessment of mycotoxin exposure is mainly based on calculations 
combining mycotoxin occurrence data in food with population data on food consumption 
(De Boevre et al., 2013; Gauchi and Leblanc, 2002; Kuiper-Goodman et al., 2010). The 
accuracy of that approach is limited due to the heterogeneous distribution of mycotoxins in 
food, the possible exposure through inhalation, the presence of masked mycotoxins, the 
influence of food processing, inter-individual variation in ADME processes and the under- 
and overestimation in food consumption data (Arcella and Leclercq, 2004). In order to 
improve and refine risk assessments, human biomonitoring has become an added value in 
evaluating exposure to mycotoxins. The direct measurement of biomarkers of exposure is 
the only available tool that integrates exposures from all sources. Biomarkers of the most 
common mycotoxins have been validated in biological fluids such as urine. The individual 
variation in ADME processes is integrated when using biomarkers, whereby a more accurate 
assessment of exposure can be performed at the individual level. Furthermore, human 
biomonitoring can demonstrate trends and changes in exposure, establish distribution of 
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exposure, identify vulnerable groups and it can reduce the assumptions regarding 
consumption rates. For this reason, the combination of exposure data from both methods 
will lead to a better interpretation in risk assessment (Choi et al., 2015). Only recently (past 
10 years), results of epidemiological studies were increasingly reported whereby the 
exposure of mycotoxins in different populations was assessed through biomarkers (Duarte et 
al., 2012; Ediage et al., 2013; Gilbert et al., 2001; Pena et al., 2006; Rubert et al., 2011; 
Turner et al., 2010a; Van der Westhuizen et al., 2011b). Exposure assessment of mycotoxins 
using biomarkers in the Belgian population was before this doctoral research (based on the 
BIOMYCO study) still missing.  
 
The BIOMYCO study was designed to assess human mycotoxin exposure based on the direct 
measurement of urinary biomarkers using validated LC-MS/MS methods. Over the different 
seasons in 2013 and 2014, morning urine was gathered in a representative part of the 
Belgian population according to a designed study protocol (chapter 5). In first instance, 
different mycotoxins and their metabolites were measured in the urine samples and 
mycotoxin exposure was described for the child and adult group (chapter 6). Second, 
mycotoxin exposure of different subgroups (age, gender, …) was compared to test whether 
exposure was significantly different between subgroups of the population. Third, links 
between the mycotoxin concentrations measured and the food consumption reported were 
estimated, to explore whether the mycotoxin exposure could be explained by the 
consumption of certain foods (chapter 7). Finally, a risk assessment was performed by 
comparing the estimated intakes with the TDI’s (chapter 6). The results of this study can be 
of interest for policy makers to get new insights in the mycotoxin issue and to help them in 
the decision-making process for the prevention and control of mycotoxin exposure. 
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CHAPTER 5  
DESIGN AND METHODS OF THE BIOMYCO STUDY 
 
 
5.1 STUDY DESIGN 
 
The BIOMYCO study was conducted according to the guidelines laid down in the declaration 
of Helsinki and was approved by the Ethical Committee of the Ghent University Hospital. All 
participants needed to sign an informed consent, whereby the informed consent for 
participating children was signed by their parents whereas a verbal assent was obtained 
from the children. Each participant was informed about their right to withdraw from the 
study at any time without any reason. Figure 5.1. schematically presents the study design of 
the project with the corresponding measurements. It is important to note that no medical 
examinations were carried out in this study and volunteers were not restricted to any diet. 
 
 
Figure 5.1. Flow diagram of the study design 
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5.1.1 Target population and sample size 
 
A sample size calculation was performed to determine the sample size needed to assess the 
exposure to mycotoxins in the target population. Because of the significant DON occurrence 
in Belgium (De Boevre et al., 2013), the sample size calculation for adults (between 19 and 
65 years old) was performed using results of an exposure assessment of DON done in the UK 
(Turner et al., 2010a). With a variance in DON concentration of 0.85, a confidence interval of 
95 % and an error of 1.10, the number of adults to be studied was estimated at 278 in order 
to get a representative view of the mycotoxin exposure in Belgium.  
 
Furthermore, young children need special attention in contaminant exposure assessment 
studies because of the quantitative higher food intake per kg body weight. For this reason, 
children within the defined age group of 3-12 years old were also recruited in this study. 
Children younger than 3 years could not participate because of logistic reasons for the 
collection of morning urine. A sample size calculation for children could not be performed 
because of the lack of information on the mean exposure to mycotoxins in this age group 
before the start of this study. We decided to recruit 140 children (being half of the sample 
size calculated for the adult group).  
Table 5.1. The representative distribution based on statistical data of Belgium in 2011 (Belgian Federal 
Government, 2011) 
ADULTS 
Age 19-34 years 35-50 years 51-65 years 
 32 % 37 % 31 % 
Region Flanders Wallonia Brussels 
 60 % 32 % 8 % 
Gender Male Female  
 50 % 50 %  
CHILDREN 
Age 3-6 years 7-9 years 10-12 years 
 40 % 30 % 30 % 
Region Flanders Wallonia Brussels 
 56 % 35 % 9 % 
Gender Male Female  
 51 % 49 %  
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5.1.2 Timeframe 
 
During the different seasons of 2013 and 2014, morning urine of adults and children was 
gathered across Belgium. Hereby, attempts were done to have a representative distribution 
for sex (male and female), age (3-6; 7-9; 10-12 and 19-34; 35-50; 51-65 years old) and 
geographical areas (Flanders, Wallonia and Brussels) within Belgium. The representative 
distribution was based on statistical data of Belgium in 2011 (Belgian Federal Government, 
2011) and can be found in table 5.1. The collection of the urine samples and the food 
questionnaires was spread over the different seasons to be able to see whether there was a 
seasonal variation. Additionally, adults recruited in the first season were asked to participate 
a second time one year later in order to investigate the year variation in their mycotoxin 
exposure.  
 
5.1.3 Cluster sampling 
 
To enable the collection of the predefined number of samples, a random cluster sampling 
was carried out. Recruitment of participants at a school and company setting for respectively 
children and adults was performed, since random sampling of Belgian adults and children 
was not realistic given the timeline and budget available in the BIOMYCO project.  
 
The companies and schools were selected by convenience based on the geographical 
location at first instance. Second, companies and schools were selected taking into account 
the variance in age and gender. The companies varied in size and served different sectors 
and training levels. Companies and schools were recruited from August 2012 onwards. The 
first step in contacting companies and schools consisted of sending an invitation letter to the 
director/principal of the company/school. Afterwards a researcher presented the study 
during a personal contact, telephone call, or provided written information about the study in 
order to explain aims and procedures. Each company/school needed to confirm its 
agreement by signing the informed consent, participated on a voluntary basis and gave 
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permission to invite their employees or children/parents to participate in the BIOMYCO 
study.  
 
5.1.4 Call for participants 
 
Participants were contacted providing an invitation letter, wherein they were informed and 
invited to participate or let their children participate in the BIOMYCO study. People could 
register for the study within two weeks after the call by signing the informed consent and by 
filling in a short questionnaire to collect some socio-demographical information. This 
information was used to control the representative distribution and could also be 
electronically collected by means of a web-based survey. All participants received a copy of 
the signed consent form. 
 
5.1.5 Recruitment strategy 
 
After registration, all general questionnaires were dealt with in the order they came in. In 
first instance, the exclusion criteria were checked: first, only one member per family could 
sign in; second, people who were exposed to a large amount of mycotoxins in another way 
than food such as farmers or veterinarians were excluded; third, persons with severe 
problems with liver, bile or kidney could not participate due to the related risk for 
interferences with the metabolism of mycotoxins and creatinine. The use of medication was 
not an exclusion criterion since there is limited information about possible interferences 
with mycotoxins. All data concerning medication was gathered in order to explain any 
possible deviant values afterwards.  
 
When people met the inclusion criteria they received an identification number in order to 
process the information anonymous. The day on which the collection would take place, was 
assigned to each participant based on representativeness (sex, age, region, education level 
and diet) and logistic organisation.  
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5.1.6 Sample collection 
 
All eligible participants received one week before the urine collection, a general 
questionnaire, a FFQ and a urine jar with instructions. These instructions contained clear 
information about how and when they had to fill in the questionnaires, when they had to 
collect their morning urine and where and when they could deliver sample and filled 
questionnaires. In agreement with the director/principal of the company/school, a room was 
reserved where the participants could hand in their questionnaires and morning urine to our 
fieldworkers. To minimise missing data, the fieldworkers immediately checked the 
completeness of questionnaires. Sample collection generally took place between 8-10 a.m. 
 
5.1.7 Transportation and storage conditions 
 
The sampling day was randomLy selected to cover all days of the week except for Saturday 
and Sunday. All urine samples were transported to the laboratory under cooling conditions, 
were divided in aliquots (20 mL) and stored at -20°C within six hours after urine collection 
for stability reasons (Ediage et al., 2012). All samples were registered in a sample book. 
 
5.2 QUESTIONNAIRES 
 
A general questionnaire was drawn up in order to collect personal and socio-demographical 
data for checking the representativeness of the population and to investigate whether 
mycotoxin exposure of different subgroups (age, …) was significantly different. Participants 
were asked for their medical history, smoking behaviour, recent medication, diet, dietary 
restrictions and socio-demographical data. Height and weight were self-reported to obtain 
individuals’ body mass index (BMI). For the children, age and sex-specific BMI z-scores were 
calculated based on the reported weight and height using Flemish 2004 growth reference 
data (Roelants et al., 2009).  
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Because of the considerable differences between the toxicokinetics of the different 
mycotoxins in human and animals (see chapter 2), a FFQ was drawn up whereby the 
consumption of some foods in the 24 hours and month prior to the urine collection was 
asked. This 43 food-item containing instrument was developed and pilot tested by 
experienced dieticians and was used as a screening instrument to investigate the food 
consumption in adults and children. The participants were asked to report the frequency of 
consumption of selected food items using following response options: never, 1-3 days a 
month, 1 day a week, 2-4 days a week, 5-6 days a week and every day. Foods were not 
weighed, but amounts of consumption were assessed using household measures such as 
glass, cup, spoon or slices (figure 5.2.).  
 
Figure 5.2. Example of the food frequency questionnaire, whereby the consumption of 43 food commodities 
in the 24 hours and month prior to the urine collection was asked 
 
 
In addition the weights of these specific food items were estimated and the intake was 
determined of each food commodity (g/day or mL/day) for each individual. In order to 
calculate the intake levels during the previous month (g/day or mL/day), a conversion factor 
was used whereby the assumption was made that every month consists of 4 weeks. To 
prevent time-consuming questionnaires, only the consumption of food commodities that are 
suspected to be contaminated with mycotoxins and are highly consumed in Belgium were 
included in the questionnaire such as breakfast cereals, bread and bakery products, rice, 
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pasta, soy products, nuts and raisins (see table 5.2.).  Other potential sources of mycotoxins 
do occur in the diet, such as in sauces and thickeners. However, their contribution to 
mycotoxin intake was estimated to be of relatively minor importance.  
 
The questionnaires were made in Dutch and French using Teleform (‘Cardiff Software’ 
Hewlett Packard, Illinois, USA) allowing electronic scanning and therefore minimising typing 
errors. Most importantly, all questionnaires were self-administered by the participants at 
home without interference of the researchers, whereby parents could fill in the 
questionnaires of their children. The questionnaire was accompanied by an instruction sheet, 
containing clear information about how and when they had to fill in the questionnaires. The 
questionnaires are in the annex of this thesis.  
 
Table 5.2. The 43 food commodities studied in the food frequency questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
Breakfast cereals 
Muesli and cruesli 
Cornflakes, rice krispies… 
Pastry and biscuits 
Cereal bar 
Ginger bread 
Biscuits 
Pancake 
Cake 
Pastry and pie 
Bread 
White 
Wholemeal 
Rye 
Raisin 
Soft white bread 
(Soft buns, brioche bread,…) 
Viennoiseries 
Rusk 
Pasta 
Wholemeal 
White 
Polenta 
Rice 
Whole grain 
White 
Nuts and dried fruit 
Assorted nuts with raisins 
Peanuts and peanut cheese 
Pistachio nuts 
Other nuts 
Dried fruit (fig, apricot…) 
Raisins 
Spices 
Paprika powder 
Chilli powder 
Soy products 
Pudding - desserts 
Tofu 
Tempeh 
Vegetarian burger 
Pizza/Durum 
Tortilla 
Drinks 
Coffee 
Beer 
Wine 
Soy 
Other 
Popcorn 
Corn-based crisps 
Seitan 
Quorn 
Maize 
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5.3 ANALYTICAL METHODS 
 
In most of the mycotoxin exposure studies with urinary biomarkers performed before the 
start of this project, urinary glucuronides were measured after enzymatic digestion with β-
glucuronidase (Turner et al., 2010a; Turner et al., 2008c). The interferences of 
mucopolysaccharides with β-glucuronidase could lead to an inefficient hydrolysis and 
possibly inaccurate results (Orti et al., 1986; Pena et al., 2006). In this project, biomarkers 
such as the glucuronides were determined in a direct way. Therefore, two previously 
described LC-MS/MS methods were further optimised and validated for the determination 
of mycotoxin biomarkers in morning urine. In total 33 mycotoxins/metabolites were 
analysed in this project (table 5.3.).  
 
Table 5.3. Mycotoxins and metabolites analysed in urine samples 
Group Mycotoxins and metabolites 
Aflatoxins AFB1  AFB2  AFG1  AFG2  AFM1 
Citrinin CIT HO-CIT 
Fumonisins FB1  FB2  FB3  HFB1 
Ochratoxins OTA - OTα 
Trichothecenes 
 
T-2 HT-2 DON DON3GlcA DON15GlcA DOM-1 DOMGlcA 
3ADON 3ADON15GlcA 15ADON 15ADON3GlcA DAS FusX 
Zearalenones ZEN  ZEN14GlcA  α-ZEL  α-ZEL7GlcA  α-ZEL14GlcA  β-ZEL  β-ZEL14GlcA 
 
 
5.3.1 LC-MS/MS method using sample clean-up 
 
The first method was the LC-MS/MS method using sample clean-up. This LC-MS/MS method 
can analyse 13 potential biomarkers (mycotoxins and metabolites) within one 
chromatographic run of 28 min according to Ediage et al. (2012) with some minor 
modifications. Within the BIOMYCO project following biomarkers were analysed: AFB1, AFM1, 
DON, DOM-1, FB1, HFB1, HT-2, OTA, Otα, T-2, ZEN, α-ZEL and β-ZEL.  
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Mycotoxin reference standards namely AFB1, HT-2, OTA, ZEN, FB1, DOM, α-ZEL and β-ZEL, 
were purchased from Sigma-Aldrich (Bornem, Belgium). T-2 toxin was purchased from 
Biopure (Tulln, Austria). DON and AFM1 were purchased from Fermentek (Jerusalem, Israel). 
OTα was obtained from Coring System Diagnostix (Gernsheim, Germany). Stock solutions of 
DON, AFM1, AFB1, HT-2, T-2, OTA, ZEN, FB1, α-ZEL and β-ZEL were prepared in methanol at a 
concentration of 1 mg/mL. DOM and OTα were obtained as solutions in acetonitrile, with a 
concentration of 100 μg/mL and 10.3 μg/mL respectively. HFB1 was synthesised by alkaline 
hydrolysis as described in Pagliuca et al. (2005). Purification of HFB1 was carried out on a 
Waters HPLC instrument coupled to a Waters Fraction Collector III (Waters, Zellik, Belgium). 
Characterisation of the synthesised compound was performed by accurate mass 
measurements using an Exactive Orbitrap mass spectrometer (Thermo Scientific, Rockwood, 
USA). Quantification was carried out by spectrophotometric measurements as described in 
the original protocols. All stock solutions were stored at -20°C. From the individual stock 
solutions, a standard mixture was prepared in methanol, stored at -20°C and renewed every 
2 weeks. 
 
The optimum conditions for sample preparation were obtained using an experimental design 
(MODDE 9.0 software, Umetrics, Malmo, Sweden). In brief, mycotoxin biomarkers were 
extracted from 5 mL urine adding 10 mL ethyl acetate/formic acid (99/1, v/v) followed by 
extraction on an orbital shaker for 20 min. Centrifugation was later performed at 4 000 x g 
for 5 min. The ethyl acetate phase was dried at 40°C under a gentle stream of nitrogen. The 
pH of the aqueous phase was adjusted to pH between 6.5 and 7 with sodium carbonate (0.4 
M) and further diluted with methanol (1/5, v/v). The biomarkers were further isolated by 
SPE based on anion exchange. The SPE cartridge was conditioned by passing 10 mL 
methanol/water (85/15, v/v) followed by 10 mL methanol. The loaded sample was allowed 
to flow-through at a flow rate of one drop per second. Afterwards the cartridge was washed 
with 1 mL water. The analytes were eluted with 5 mL methanol/formic acid (99/1, v/v). The 
eluate was combined with the residue obtained after extraction and the pooled extract was 
evaporated at 40°C. The residue of the combined fractions was reconstituted in 200 µL 
injection solvent which consisted of water/methanol/formic acid (61.8/37.9/0.3, v/v/v). 
Hexane (500 µL) was added and the mixture was vortexed for 1 min. The content was 
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brought into a centrifugal filter and after centrifugation for 5 min at 14 000 x g, a 150 µL 
aliquot of the aqueous phase was transferred to a vial for LC-MS/MS analysis. Isotope 
labelled internal standards for AFB1, DON, FB1, OTA and ZEN were added before LC-MS/MS 
analysis.  
 
Detection and quantification were performed with a Waters Acquity UPLC® system coupled 
to a Micromass Quattro Micro triple quadruple spectrometer (Waters, Milford, MA, USA). 
The mass spectrometer analyses were carried out using multiple reaction monitoring mode 
and ionisation was performed in the positive electrospray ionisation (ESI) mode. The 
analytical column used was an Agilent ZORBAX SB-C18 (100 mm × 2.1 mm i.d., 3.5 µm). Two 
solvent mixtures were used as mobile phases, both containing 5 mM ammonium formate. 
Solvent A consisted of water/formic acid (99.7/0.3, v/v) while methanol/water/formic acid 
(94.7/5/0.3, v/v/v) was used as solvent B. The sample injection volume was 20 µL. A solvent 
gradient (flow rate of 0.25 mL min−1) was adopted for a total run time of 28 min. The solvent 
gradient was as follows: 0-1 min, 90 % A; 1-5 min, 90-50 % A, 5-10 min, 50-35 % A; 10-15 min, 
35-20 % A; 15-25 min, 20-90 % A; 25-28 min, 90 % A. The primary transition of the most 
abundant product ion was used for quantification while the secondary transition was used 
for confirmation. Quantification was carried out with matrix-matched calibration curve 
whereby blank urine samples were used.  
 
This method was validated following the guidelines of Commission Decision 2002/657/EC 
and Commission Regulation 401/2006/EC whereby LOD, limit of quantification (LOQ), 
apparent recovery, precision, selectivity/specificity and linearity were determined using 
blank urine samples. The lack of fit test for linearity resulted in p-value > 0.05 for all the 
analytes which illustrates the reliability of the chosen calibration range(s) for the 
quantification of the different analytes in real samples. In addition, the coefficient of 
determination (R²) was also determined and was between 0.9774-0.9994 for all the different 
analytes. The apparent recovery data evaluated at concentrations of 10 times the method 
LOQ for the different analytes were expressed as bias. The values ranged from 1-15 % for all 
the compounds. The intra-day and inter-day precision values were in the range 5-19 % and 
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8-29 % respectively. The calibration range, LOD and LOQ for each analyte is shown in table 
5.4. Other instrumental parameters and detailed information about this method can be 
found in Ediage et al. (2012).  
 
Table 5.4. Concentration range, LOD and LOQ of the different analytes 
Analytes Concentration range (ng/mL) LOD (ng/mL) LOQ (ng/mL) 
DON 5-50 2.85 5.70 
DOM 5-100 0.65 1.30 
AFM1 0.05-10 0.01 0.02 
OTα 0.1-20 0.03 0.06 
AFB1 2-20 0.83 1.66 
HFB1 1-50 0.51 1.02 
HT-2 1-20 0.42 0.84 
β-ZEL 5-20 1.10 2.20 
FB1 0.2-20 0.05 0.10 
T-2 0.2-20 0.05 0.10 
α-ZEL 2-20 0.61 1.22 
ZEN 5-50 1.24 2.48 
OTA 0.1-10 0.03 0.06 
 
 
5.3.2 LC-MS/MS method without sample clean-up 
 
The second method was the LC-MS/MS method without sample clean-up. This LC-MS/MS 
method can analyse 32 potential biomarkers (mycotoxins and metabolites) within two 
chromatographic runs of each 30 min. Within the BIOMYCO project following biomarkers 
were analysed: AFB1, AFM1, AFB2, AFG1, AFG2, CIT, HO-CIT, DAS, DON, DON3GlcA, 
DON15GlcA, 3ADON, 3ADON-15-glucuronide (3ADON15GlcA), 15ADON, 15ADON-3-
glucuronide (15ADON3GlcA), DOM-1, DOMGlcA, FB1, FB2, FB3, FusX, HT-2, OTA, OTα, T-2, 
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ZEN, ZEN14GlcA, α-ZEL, α-ZEL-7-glucuronide (α-ZEL7GlcA), α-ZEL-14-glucuronide (α-
ZEL14GlcA), β-ZEL and β-ZEL-14-glucuronide (β-ZEL14GlcA). 
Standards of FB1, FB2 and FB3 were purchased from Cfm Oskar Tropitzsch (Marktredwitz, 
Germany) in powder form. DOM-1, AFB1, AFB2, AFG1, AFG2, DON, OTA, ZEN and T-2 were 
purchased in powder form Romer Labs (Tulln, Austria). 3ADON, 15ADON, α-ZEL, β-ZEL and 
HT-2 were purchased from Sigma-Aldrich (Bornem, Belgium). These were dissolved in pure 
acetonitrile or in a mixture of acetonitrile/water (1/1 v/v). HO-CIT was purchased from 
AnalytiCon Discovery GmbH (Potsdam, Germany) and dissolved in acetonitrile. AFM1, DAS, 
CIT, OTα and FusX were purchased from Romer Labs as certified calibrant solutions. These 
solutions were stored at −20 °C. DON3GlcA was synthesised as described in Versilovskis et al. 
(2012) and the structure was confirmed from nuclear magnetic resonance analysis. 
DON3GlcA was quantified using UV-spectroscopy and confirmed by liquid chromatography-
diode array detection. The synthesis and structure confirmation of DON15GlcA was 
described in Uhlig et al. (2013). The structures of all other glucuronides (DOMGlcA, 
ZEN14GlcA, β-ZEL14GlcA, α-ZEL7GlcA, α-ZEL14GlcA, 15ADON3GlcA, 3ADON15GlcA) were 
tentatively identified as described in Versilovskis et al. (2012). The concentration of 
DON15GlcA was determined based on the calibration curve using DON3GlcA. All other 
glucuronides were quantified semi-quantitatively, as not enough pure compounds were 
available for weighing. 
 
Prior to the start of analysis all urine samples were centrifuged at 10 000 rpm for 5 min. A 2 
mL portion was filtered with a syringe filter (0.2 µm). Detection and quantification were 
performed with a Waters Acquity UPLC® H-Class system coupled to a Xevo TQ-S 
spectrometer (Waters, Milford, MA, USA). The mass spectrometer analyses were carried out 
using multiple reaction monitoring mode and ionization was performed in the positive and 
negative ESI mode. The analytical column used was a Waters HSS T3 (100 mm x 2.1 mm i.d.; 
1.8 µm). Water and methanol were used as mobile phases, both containing 5 mM 
ammonium acetate and 0.05 % acetic acid in positive ESI mode and 0.1 % acetic acid in 
negative ESI mode. The sample injection volume was 10 µL. A solvent gradient (flow rate of 
0.5 mL min−1) was adopted for a total run time of 30 min. The gradient program started at 
2.5 % methanol; after a plateau for 2 min at initial conditions, it increased to subsequently 4 % 
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in 6 min, 10 % at 10 min and reached 75 % at 27 min. The column was then washed with 99 % 
methanol for 1 min and equilibrated at initial conditions for 2 min. Quantification was 
carried out using an external calibration curve and correction for matrix suppression or 
enhancement.  
Table 5.5. Concentration range, LOD and LOQ of the different analytes 
Analytes Concentration range (ng/mL) 
LOD 
(pg/mL) 
LOQ 
(pg/mL) 
 
DON/DON3GlcA/DON15GlcA/DOMGlcA 
FusX/β-ZEL/ZEN14GlcA/HT-2 
 
0.5-20.0 
0.5-20.0 
 
200 
200 
 
500 
500 
3ADON15GlcA/15ADON3GlcA  
OTα/α-ZEL7GlcA/β-ZEL/α-ZEL  
FB1/FB3/ FB2 
0.5-20.0 
0.5-20.0 
0.5-20.0 
50 
50 
50 
200 
200 
200 
DOM-1/3ADON/15ADON/α-ZEL14GlcA 0.5-20.0 100 300 
HO-CIT/ T-2 0.5-20.0 10 30 
AFG2 0.05-2 10 30 
AFM1 0.05-2 2 5 
AFG1/ AFB2/ AFB1 0.05-2 5 20 
DAS 0.5-20.0 5 20 
CIT 0.5-20.0 1 3 
OTA 0.05-2 1 3 
ZEN 0.5-20.0 20 50 
 
This method was validated for most of the 32 biomarkers following the guidelines of 
Commission Decision 2002/657/EC and Commission Regulation 401/2006/EC whereby LOD, 
LOQ, reproducibility, repeatability and linearity were determined using blank urine samples. 
Calibration curves generated R² values of at least 0.95. The RSDRw values were less then 20 % 
for 25 analytes, 23 % for DON, and between 31 and 41 % for DOM-1, 3ADON15GlcA, 
15ADON3GlcA and β-ZEL14GlcA. The calibration range, LOD and LOQ for each analyte is 
shown in table 5.5. More detailed information about this method can be found in 
(Huybrechts et al., 2014). 
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5.3.3 Creatinine determination with spectrophotometry  
 
The analysis of urinary mycotoxin biomarkers excretion in 24 hours samples is an accurate 
method to assess exposure. However, the collection of 24 hours urine is very aggravating for 
the participants, difficult for children and time-consuming. Therefore morning urine was 
used as alternative in order to prevent the drop out of participants, whereby the obtained 
biomarker concentrations were normalized in function of the creatinine content to correct 
for variable dilutions (Turner et al., 2010a). The urinary creatinine level was measured 
through an in-house spectrophotometric method based on the principle of Jaffe’s reaction. 
Briefly, 18 mM picric acid reacts with 85 mM sodium hydroxide to form alkaline picrate. 
Alkaline picrate (2 mL) reacts with 1 mL of diluted urine (1/100, v/v, in ultrapure water). The 
optical density was measured at 495 nm after 25 min using a Philips PU 8620 
spectrophotometer (Ediage et al., 2012). Furthermore, creatinine concentrations were used 
to determine whether the spot urinary sample was valid. The World Health Organization 
(WHO) recommends that if a sample is too diluted (creatinine concentration <30 mg/dL) or 
too concentrated (creatinine concentration >300 mg/dL), another urine void should be 
collected (WHO, 1996). For this reason, 42 urine samples with creatinine concentrations out 
of this range were excluded from the project. 
 
Urinary creatinine concentrations are widely used to adjust urinary concentrations of 
chemicals or their metabolites. The formation of urinary creatinine and the ways in which 
various factors may affect its concentration are important. The rate of creatinine formation 
is fairly constant, but this rate decreases with age in adults (Alessio et al., 1985). Researchers 
found a high correlation between urinary creatinine concentrations and muscle mass 
(Edwards and Whyte, 1959). In addition, men have higher levels of creatinine than women 
and persons with a high red meat intake have higher levels in comparison with persons with 
a low red meat intake (Bjornsson, 1979; Lykken et al., 1979). Furthermore, if an analyte is 
excreted predominantly through passive secretion in the kidney, the analyte secretion will 
vary with urine flow rate and creatinine adjustment will not correct for urine dilution. Due to 
these reasons the use of creatinine-adjusted metabolite concentrations in order to 
accurately compare exposures among the study participants remains a subject of research 
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(Barr et al., 2005; Boeniger et al., 1993). Within this study, biomarker concentrations were 
presented both corrected and uncorrected for creatinine levels.  
 
5.4 STATISTICAL ANALYSIS 
 
The data from the questionnaires and the results from the chemical analysis of the urine 
samples were linked to each other via the identification number and were put together in 
one central database. When all data was collected, this database was cleaned whereby all 
data were checked for intolerable values. Afterwards the data were used for statistical 
analysis. Urinary biomarker data were used as a direct indicator of mycotoxin exposure, 
without relating it yet to food consumption. These obtained biomarker concentrations were 
presented both uncorrected and corrected for creatinine levels (the latter to correct for 
variation in urinary concentration). When two different concentrations were obtained (cf. 
two LC-MS/MS methods) the highest concentrations were used for further calculations (= 
worst case). The concentration of DON15GlcA was based on a calibration curve using 
DON3GlcA, because only a small amount of standard was available.  
 
Additionally, mycotoxin exposure of different subgroups was compared to investigate 
whether exposure of these subgroups was significantly different using non-parametric tests 
being the Mann-Whitney U and Kruskal-Wallis tests. The association between BMI and 
mycotoxin exposure was investigated using a Spearman correlation analysis. Furthermore, 
this study investigated if the consumption of different food items or food groups could 
predict the concentrations measured in urine. The population was divided in two classes for 
each food commodity (consumers and non-consumers). The normality of each class was 
tested using the Shapiro-Wilkinson test. In a next step, the mycotoxin concentrations (both 
corrected and uncorrected for creatinine) were compared between the different classes 
using the non-parametric Mann-Whitney-U test. When less than 5 individuals consumed a 
specific food commodity, the results of the statistical analysis were not reported. Data was 
analysed using SPSS software version 21 (p-value < 0.05 was considered as statistically 
significant). All results were communicated to the authorities. 
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CHAPTER 6  
HUMAN BIOMONITORING OF MULTIPLE MYCOTOXINS IN THE BELGIAN 
POPULATION: RESULTS OF THE BIOMYCO STUDY 
 
 
6.1 POPULATION CHARACTERISTICS 
 
A sample of 217 children, aged 3-12 years, were enrolled for the study. Based on the 
exclusion criteria, seven of the recruited children were excluded (age, kidney problem, other 
participating family member). Another 37 children forgot to collect their urine. Overall 173 
subjects returned a urine sample and a completed questionnaire between January 2013 and 
March 2014. Twelve of these children had no valid urine samples (too diluted, too 
concentrated, not enough volume) and 6 children did not fill in all the necessary data. A total 
of 155 children were included (118 from Flanders and 37 from Wallonia) consisting of 67 
boys and 88 girls.  
 
Figure 6.1. Location of sampling in Belgium  
 
  
ADULTS (n=239) CHILDREN (n=155) 
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Table 6.1. The socio-demographical data of the children and adults at time of sampling are compared to the 
socio-demographical distribution needed (see table 5.1.) 
 ADULTS (n = 239) 
Age  19-34 years 35-50 years 51-65 years 
 Participated 91 (38  %) 99 (41  %) 49 (21  %) 
 Needed 32 % 37 % 31 % 
Region  Flanders Wallonia Brussels 
 Participated 173 (72  %) 50 (21  %) 16 (7  %) 
 Needed 60 % 32 % 8 % 
Gender  Male Female  
 Participated 106 (44  %) 133 (56  %)  
 Needed 50 % 50 %  
 CHILDREN (n = 155) 
Age  3-6 years 7-9 years 10-12 years 
 Participated 65 (42  %) 46 (30  %) 44 (28  %) 
 Needed 40 % 30 % 30 % 
Region  Flanders Wallonia Brussels 
 Participated 118 (76  %) 37 (24  %) 0 (0 %) 
 Needed 56 % 35 % 9 % 
Gender  Male Female  
 Participated 67 (43  %) 88 (57  %)  
 Needed 51 % 49 %  
 
 
The second population sample included adults aged 19 to 65 years. A number of 427 adults 
were enrolled for this study. Five of the recruited adults could not participate according to 
the exclusion criteria (contact with feed, problems with liver, bile or kidney) and another 131 
adults did not show up or forgot to collect their urine. Overall 291 subjects returned a urine 
sample and a completed questionnaire between January 2013 and March 2014. Fifty two 
adults had no valid urine samples (too diluted, too concentrated, not enough volume). A 
total of 239 adults were included (173 in Flanders, 50 in Wallonia and 16 in Brussels) 
consisting of 106 men and 133 women. The location of sampling in Belgium is presented in 
figure 6.1. and the flow chart describing the selection procedures is illustrated in figure 6.2. 
In table 6.1. the socio-demographical data of the children and adults at time of sampling are 
compared to the socio-demographical distribution needed (table 5.1.). It has to be noted 
that Brussels accounts for only 8 % of the Belgian population. Flanders has most inhabitants 
(58  %), whereas Wallonia has less inhabitants (33  %).  
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Figure 6.2. Flow chart describing the selection procedure of the studied sample (n=394) 
 
6.2 PREVALENCE OF MYCOTOXINS IN BELGIAN URINE 
 
In total, 394 urine samples from children and adults living in Belgium were analysed for the 
presence of 33 urinary mycotoxins and their metabolites. Nine out of 33 mycotoxins were 
detected whereby DON, OTA, CIT and their metabolites DON3GlcA, DON15GlcA, DOMGlcA 
and HO-CIT were the most frequently detected. DON15GlcA was the main urinary DON 
biomarker found and for the first time DOMGlcA was detected in urine of children. 
Furthermore α-ZEL was detected in one urine sample and β-ZEL14GlcA in two samples. AFB1, 
AFB2, AFG1, AFG2, AFM1, FB1, FB2, FB3, HFB1, DAS, 3ADON, 3ADON15GlcA, 15ADON, 
15ADON3GlcA, DOM-1, FusX, HT-2, OTα, T-2, ZEN, ZEN14GlcA, α-ZEL7GlcA, α-ZEL14GlcA and 
β-ZEL could not be detected or quantified in urine samples from the Belgian population. The 
incidence, mean, median, minimum and maximum levels of these mycotoxins are 
summarised in table 6.2 (uncorrected and corrected for creatinine) whereby only data above 
LOQ were used. The concentration of DON15GlcA was based on a calibration curve using 
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DON3GlcA, because only a small amount of standard was available. When two different 
concentrations were found for DON (21/198), OTA (1/163) and α-ZEL (1/1) (cfr. two LC-
MS/MS methods), the highest concentrations (= worst case) were used in further 
calculations. Examples of chromatograms of contaminated urine samples are presented in 
table 6.3.  
 
An overall incidence of DON was measured in 70 % of the children and 37 % of the adults 
with a mean concentration of 5.5 ng/mg creatinine for children and 6.1 ng/mg creatinine for 
adults. DON15GlcA was the most frequently detected biomarker (in 100 % of the samples) 
with mean levels of 65.3 and 50.1 ng/mg creatinine for children and adults respectively. 
While DON15GlcA is the main biomarker of DON in humans, DON3GlcA was detected in 91 % 
of the urine samples from children with a mean concentration of 12.3 ng/mg creatinine. For 
adults, 77 % of the urine samples were positive for DON3GlcA with a mean concentration of 
6.7 ng/mg creatinine. For the first time DOMGlcA was detected in urine samples of children. 
The incidence in children was 17 % with a mean concentration of 100.9 ng/mg creatinine. 
For adults, DOMGlcA was detected in 22 % of the samples with a mean concentration of 25.0 
ng/mg creatinine.   
 
Results showed that 51 % of the urine samples from children and 35 % of the urine samples 
from adults were OTA contaminated. The mean concentration was 83.2 pg/mg creatinine 
and 36.4 pg/mg creatinine for children and adults respectively. Despite its high occurrence 
(72 % for children and 59 % for adults), the average urinary concentrations of CIT were low 
(same range as OTA), being 39.8 pg/mg creatinine and 73.3 pg/mg creatinine for children 
and adults respectively. Also the metabolite of CIT, namely HO-CIT, was detected in 6 % of 
the children and 12 % of the adults. The mean concentration of HO-CIT was tenfold higher 
than CIT. α-ZEL was only found in one sample and β-ZEL14GlcA in two urine samples of 
adults. None of these mycotoxins were found in children.   
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6.3 PATTERNS IN MYCOTOXIN EXPOSURE 
 
Table 6.4. shows moderate to strong correlations (r= 0.5-0.8) between urinary 
concentrations of DON, DON3GlcA and DON15GlcA. These correlations were both found in 
adults and children, whereby the urinary concentrations were corrected and uncorrected for 
creatinine. These correlations suggest that humans are efficiently conjugating DON with 
glucuronic acid and confirm earlier reports (Huybrechts et al., 2014).  
 
Table 6.4. Pairwise comparison of the different biomarkers using the p-value(s) 
Population  
group 
Mycotoxin 
 
Uncorrected 
for creatinine 
Corrected 
 for creatinine 
n r p n r p 
Children 
 
DON-DON3GlcA 155 0.572 < 0.001 106 0.566 < 0.001 
DON-DON15GlcA 155 0.671 < 0.001 109 0.607 < 0.001 
DON3GlcA-DON15GlcA 155 0.751 < 0.001 141 0.718 < 0.001 
Adults 
DON-DON3GlcA 239 0.433 < 0.001 76 0.309 0.007 
DON-DON15GlcA 239 0.410 < 0.001 89 0.226 0.033 
DON3GlcA-DON15GlcA 239 0.717 < 0.001 184 0.795 < 0.001 
n: amount of urine samples; r: Spearman rank correlation coefficient; p < 0.05 is statistical significant; Half the 
value of their respective LOD’s (=100 pg/mL) were assigned to samples with no quantifiable biomarkers. When 
concentrations corrected for creatinine were used, only positive samples were used (>LOQ). 
 
6.4 RISK ASSESSMENT 
 
A risk assessment was performed by comparing the estimated dietary intake of DON and 
OTA with their TDI. Exceeding the TDI can imply a possible health risk for the Belgian 
population. The dietary intake of DON and OTA was estimated using the urinary 
concentrations. The calculated intake was compared to the following TDI’s:  
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• DON (including acetylated DON’s) = 1 µg/kg BW/day (FAO/WHO, 2010) 
• OTA = 0.017 µg/kg BW/day (Schlatter et al., 1996), based on TWI of 0.12 µg/kg 
BW/week  (EFSA, 2006) 
 
Currently, there are different methods available to calculate the estimated exposure through 
urinary levels. Following calculations were reported:  
 
1 Estimated dietary intake DON μg/kg. BW/day =
%&' ∗ )
*+ ∗ ,- ∗ 1000
 
Reported by Gratz et al. (2014); Wallin et al. (2013); Rodriguez-Carrasco et al. (2014b); Turner et al. (2010b)  
2  Estimated dietary intake DON μg/kg. BW/day =
%&' + %&'32345 + %&'152345 + %&72345 ∗ )
*+ ∗ ,- ∗ 1000
 
Reported by Ezekiel et al. (2014) 
3  Estimated dietary intake DON μg/kg. BW/day =
%&' + %&'32345 + %&'152345 ∗ 0.63 + %&72345 ∗ 0.65 ∗ )
*+ ∗ ,- ∗ 1000
 
Reported by Warth et al. (2012b) 
4 Estimated dietary intake DON μg/kg. BW/day =
%&' + %&'32345 + %&'152345 ∗ 0.63 + %&72345 ∗ 0.65 ∗ )
*+ ∗ ,- ∗ :; ∗ 1000
 
Reported by Sarkanj et al. (2013) 
5  Estimated dietary intake OTA μg/kg. BW/day =
&=5 ∗ )
*+ ∗ ,- ∗ 1.000.000
 
Reported by Ezekiel et al. (2014) 
 
Assumptions made: 
ER = % of ingested DON excreted in urine = 72 % (Turner et al., 2010b) 
      = % of ingested OTA excreted in urine = 50 % (Schlatter et al., 1996) 
V = daily urine production of adults is 1500 mL and children is 1000 mL (Turner et al., 2010b) 
BW  = body weight (kg) reported in questionnaire 
CF  = concentration factor, morning urine is 2 times more concentrated than urine during day (Warth et al., 2013a) 
DON/DON3GlcA/DON15GlcA/DOMGlcA = urinary concentration not corrected for creatinine (ng/ml) 
OTA = urinary concentration not corrected for creatinine (pg/ml) 
Factor 0.63 and 0.65 was obtained by calculating DON-equivalents  (see section 7.1) 
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It has to be highlighted that these calculations are based on excretion rate assumptions and 
that inter-individual variations were not taken into account. Due to the lack of toxicokinetic 
data on mycotoxins in human, there are still a lot of uncertainties that should be taken into 
account when perform a risk assessment based on urinary mycotoxin levels. The dietary 
intake of DON was in formula 1 estimated based on the individual urinary DON levels. The 
use of this formula leads to an underestimation of the DON exposure as no metabolites were 
taken into account. Formula 2 does not take into account the molar masses of the DON 
metabolites. Furthermore in formula 1, 2, 3 and 5 the assumption was made that morning 
urine is equally concentrated than urine collected during the day, leading to an 
overestimation. In formula 4 the difference in concentration of morning urine and urine 
collected during the day was taken into account. Additionally, the presence of unknown 
metabolites can lead to an underestimation. The quantification of DON15GlcA was based on 
the concentration of DON3GlcA, because of the small amount of standard solution available. 
When enough standard solution of DON15GlcA is available in the future, these data can be 
corrected. Because no standard method is available at this moment for calculating the 
estimated exposure through urinary concentrations, the dietary exposure within the 
BIOMYCO study was calculated in two different ways (formulae 3 and 4). This approach will 
enable the comparison with other exposure assessments performed in different European 
countries. All the different estimated intakes are presented in table 6.5.  
 
The estimated intake for DON varies between 0.11 – 19.57 µg/kg BW/day for children and 
0.03 – 10.08 µg/kg BW/day for adults. Of total exposed subjects 56-69 % of children and 16-
39 % of the adults were estimated to exceed the TDI. For OTA the individually urinary level 
was used to carry out an exposure assessment. The estimated intake for OTA was between 
0.2 – 100 ng/kg BW/day for children and  0.1 – 21 ng/kg BW/day for adults. In total 1 % of 
the Belgian population exceeded the TDI for OTA.  
 
Due to the lack of toxicokinetic data for CIT, no risk assessment could be performed for this 
mycotoxin.  
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In general, in this kind of exposure assessments young children need special attention 
because of the quantitative higher food intake per kg body weight. In order to perform more 
accurate estimations, more research needs to be done in order to collect more information 
about the human metabolism of mycotoxins, especially for CIT. More exposure assessment 
studies are needed in order to compare the different estimates and to evaluate the 
variability amongst people.  
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CHAPTER 7  
URINARY MYCOTOXIN BIOMARKERS IN RELATION TO  
FOOD CONSUMPTION AND SOCIO-DEMOGRAPHICAL CHARACTERISTICS 
IN BELGIAN CHILDREN AND ADULTS 
 
 
7.1 URINARY BIOMARKERS IN RELATION TO SOCIO-DEMOGRAPHICAL 
CHARACTERISTICS 
 
Socio-demographical data of the children and adults at time of sampling are summarized in 
table 7.1. The incidence, mean, median, minimum and maximum levels of the urinary 
mycotoxin biomarkers are presented in table 6.2. (uncorrected and corrected for creatinine). 
Because metabolites are formed in the human body and are not present in food, DON-
equivalents were calculated using the concentrations of DON3GlcA, DON15GlcA and 
DOMGlcA. These equivalents were further used to investigate the relationship between 
socio-demographical characteristics and urinary biomarkers. The same calculations were 
performed for CIT.  
 
%&' − ?@ABCD3?EFG 
6 = %&' +
HIJKLMNOPHIJQRLMNO∗ST HIJ
ST HIJLMNO
+
HISLMNO∗ST HIJ
ST HISLMNO
  
:U= − ?@ABCD3?EFG 
7 = :U= +
WIXYZ[∗ST YZ[
ST WIXYZ[
  
With  
DON/DON3GlcA/DON15GlcA/DOMGlcA = urinary concentration uncorrected for creatinine (ng/mL) 
CIT/HO-CIT = urinary concentration uncorrected for creatinine (pg/mL) 
MW = molecular weight (DON = 296, DONGlcA = 472, DOMGlcA = 456, CIT = 250, HO-CIT = 266) 
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Table 7.1. Socio-demographical data of the children and adults at time of sampling 
CHILDREN (n=155) ADULTS (n=239) 
Gender  Gender  
Boy 67 Male 106 
Girl 88 Female 133 
Age  Age  
3-6 years 65 19-34 years 91 
7-9 years 46 35-50 years 99 
10-12 years 44 51-65 years 49 
Region  Region  
Flanders 118 Flanders 173 
Wallonia 37 Wallonia 50 
Brussels 0 Brussels 16 
Mean weight in kg (min-max) 27 (12-55) Mean weight in kg (min-max) 72 (40-129) 
Mean height in cm (min-max) 127 (93-158) Mean height in cm (min-max) 173 (149-205) 
Mean BMI kg/m² (min-max) 16 (12-25) Mean BMI kg/m² (min-max) 24 (17-42) 
Mean BMI z-score (min-max) 0.837 (0.003-3.385)   
Dietary restrictions 
Gluten free 
Lactose free 
Egg white free 
Losing weight 
Low-fat or cholesterol 
Low-salt  
Diabetes 
No nuts 
No fish 
No information 
 
1 
0 
2 
0 
1 
0 
0 
2 
1 
8 
Dietary restrictions 
Gluten free 
Lactose free 
Egg white free 
Losing weight 
Low-fat or cholesterol  
Low-salt  
Diabetes 
No sulfites 
No fruit 
No caffeine 
No information 
 
3 
5 
1 
5 
4 
2 
0 
1 
1 
1 
10 
Diets 
West-European 
Mediterranean 
Oriental 
Halal 
Kosher 
Limited meat intake 
Vegetarian 
Vegan 
Combination 
No information 
 
107 
2 
0 
2 
0 
2 
2 
0 
30 
10 
Diets 
West-European 
Mediterranean 
Oriental 
Halal 
Kosher 
Limited meat intake 
Vegetarian 
Vegan 
African 
Combination 
No information 
 
135 
2 
0 
0 
0 
13 
10 
1 
1 
68 
9 
  Smoking behaviour  
  Smokers 19 
  Non-smokers 215 
  No information 5 
  Pregnant women 5 
  Breast-feeding women 1 
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The urinary biomarker concentrations measured in this Belgian population differed 
significantly among age and gender. Children from 3 to 6 years old were exposed to lower 
levels of DON (based on DON-equivalents, p-value 0.032) in comparison with children from 
10 to 12 years old. No significant differences concerning urinary biomarker levels between 
girls and boys were found. In contrast, in the adult group men showed significantly higher 
levels of DON (based on DON-equivalents, p-value 0.014) in comparison with women. Adults 
between 19 and 34 years old had significantly lower urinary levels of OTA (p-value 0.012) 
than adults from 51 until 65 years old. All concentrations used for these data analysis were 
uncorrected for creatinine due to the fact that creatinine was correlated to some of these 
socio-demographical characteristics. Additionally a significantly negative correlation was 
found between BMI and creatinine-adjusted levels of DON3GlcA (r= -0.167, p= 0.025, n= 181) 
and DON15GlcA (r= -0.156, p= 0.021, n= 235) in adults and creatinine-adjusted levels of CIT 
(r= -0.219, p= 0.030, n= 99) in children using a Spearman correlation analysis. A positive 
correlation was found between BMI and creatinine-adjusted HO-CIT levels (r= 0.571, p= 
0.041, n= 13) in adults.  
 
Furthermore, the difference in exposure between different diets was investigated. Most of 
the Belgian people consumed a West-European diet (table 7.1.). Also Mediterranean, Halal, 
African, limited meat intake, vegetarian, vegan diets or a combination were reported in the 
questionnaire. Because of the limited number of subjects, a statistical analysis could not be 
performed for some of these subgroups. For children only a significant difference could be 
seen between children who followed a West-European diet (n=87) and children who 
followed a combination of different diets (n=21), whereby children with only a West-
European diet had significantly higher levels of creatinine-adjusted DON in their urine 
(p=0.034). However, it has to be remarked that this trend should be confirmed by future 
research. The difference in exposure between different dietary restrictions for children and 
adults and between breast-feeding women and no breast-feeding women could not be 
analysed due to the limited number of subjects within these subgroups. A significant 
difference could be seen for pregnant women whereby the levels of CIT-equivalents (p= 
0.013, n=5) were lower in comparison with non-pregnant women. Also the urinary levels of 
creatinine-adjusted OTA were lower for the pregnant women (p=0.045, n=3). However, it 
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has to be remarked that the number of subjects was too small to have an accurate analysis. 
This trend should be confirmed by future research. Finally, no significant difference in 
exposure between smokers and non-smokers could be seen.  
 
7.2 URINARY MYCOTOXIN BIOMARKERS IN RELATION TO FOOD 
CONSUMPTION 
 
The total intake (g/day or mL/day) of the 43 food commodities reported by Belgian adults 
and children (n=394) was calculated based on the data collected with the FFQ (table 7.2). 
The incidence and mean levels of the urinary mycotoxin biomarkers are presented in table 
6.2 (uncorrected and corrected for creatinine). Because metabolites are formed in the 
human body and are not present in food, DON- and CIT-equivalents were used to investigate 
the relationship between food intake and urinary biomarkers (see 7.1. for formulae).  
 
The urinary OTA levels were compared between consumers and non-consumers of 43 
different food commodities consumed in the month previously to the urine collection. All 
significant differences found, are presented in table 7.3. Children who consumed raisin 
bread, rusk or whole grain rice showed higher OTA levels in comparison with non-consumers. 
Adults who consumed pancakes, had higher levels of urinary OTA. Despite the reported 
occurrence of OTA in dried fruits and nuts, children who consumed assorted nuts with raisins 
had lower levels of OTA than the non-consumers. Children who consumed white bread and 
vegetarian burgers had lower levels of OTA in comparison with the non-consumers. The 
same trend was seen by the adults namely consumers of cereal based products (white bread, 
wholemeal bread, pizza or durum and white pasta) had significantly lower levels of OTA.  
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The urinary levels of DON, CIT, DON-equivalents and CIT-equivalents between consumers 
and non-consumers of 43 different food commodities consumed on the day prior to the 
urine collection were compared, for children and adults. All significant differences found are 
presented in table 7.4. Children who consumed raisin bread had higher levels of DON-
equivalents in their urine and higher levels of urinary DON were present in the urine of 
children who consumed soft white bread. On the contrary, children who consumed muesli, 
cruesli and cornflakes had lower levels of DON and consumers of raisins had lower levels of 
DON-equivalents. For the adults, no significant differences on the level of food consumption 
could be found for DON-equivalents. Consumers of beer, corn-based crisps and chilli powder 
had significantly higher levels of DON. This is in contrast with adults who drank coffee, they 
had significantly lower levels. 
 
Within the BIOMYCO study significantly higher CIT levels were present in the urine of 
children consuming biscuits, whereas consumers of pizza or durum and seitan had 
significantly lower levels of CIT. The consumption of cornflakes and white pasta showed 
significantly higher levels of CIT-equivalents in urine of children in comparison with non-
consumers. The consumers of viennoiseries and corn-based crisps had significantly lower 
levels of respectively CIT and CIT-equivalents in adults.  
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CHAPTER 8  
GENERAL DISCUSSION 
 
 
8.1 MAIN FINDINGS AND COMPARISON WITH LITERATURE  
 
8.1.1 Study design 
 
Mycotoxins form a worldwide problem and therefore human exposure to these toxins 
should be assessed. Human exposure to mycotoxins can be assessed by two major 
approaches: based on calculations combining mycotoxin contamination data in food with 
population data on food consumption (De Boevre et al., 2013; Gauchi and Leblanc, 2002; 
Kuiper-Goodman et al., 2010) and mycotoxin analysis (biomarkers) in biological fluids (e.g. 
urine).  
 
Within the BIOMYCO study 394 urine samples were collected from healthy children and 
adults in Belgium for mycotoxin analysis. Participants were asked for their medical history, 
smoking behaviour, recent medication, dietary intake, diet restrictions and socio-
demographical data through a general questionnaire. Furthermore, every participant 
completed a FFQ to assess the consumption of relevant foods (n=43) on both the day and 
the month prior to the urine collection.  
 
The biomarker approach is particularly useful as it covers mycotoxin exposure by all routes 
(oral, dermal, inhalation). Moreover, collection of urine is an easy and non-invasive sampling 
method. Thanks to the high sensitivity of the recently developed analytical instruments, 
different LC-MS/MS methods for the detection and quantification of biomarkers in urine 
were developed in order to assess mycotoxin exposure (Ediage et al., 2012; Gambacorta et 
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al., 2013; Solfrizzo et al., 2011b; Solfrizzo et al., 2013; Song et al., 2013; Warth et al., 2011; 
Warth et al., 2013b). These LC-MS/MS methods were validated in pilot surveys on a small-
scale. Only recently (past 10 years), studies were increasingly reported whereby the 
exposure of mycotoxins in different populations was assessed through biomarkers of 
exposure.  
 
Pena et al. (2006) and Duarte et al. (2012) estimated the exposure of OTA in the Portuguese 
population, whereas Gilbert et al. (2001) assessed the dietary exposure of OTA in 50 
individuals in the UK using a duplicate diet approach. FB1 was used as an urinary biomarker 
of exposure in a maize intervention study among South African subsistence farmers (Van der 
Westhuizen et al., 2011b), whereas sphingoid base levels in humans consuming fumonisin-
contaminated maize were investigated in rural areas of the former Transkei in South Africa 
(Van der Westhuizen et al., 2008). In 2012 exposure assessment to Fusarium toxins was 
performed in 110 women from Iran (Turner et al., 2012). In France, urinary DON and DOM-1 
were determined in urine of male farmers (Turner et al., 2010a). Turner et al. (2008b) linked 
urinary DON with cereal intake in individuals from the UK. Whereas most of these studies 
focus on the exposure of one mycotoxin, Ediage et al. (2013) conducted a study to 
investigate the mycotoxin exposure in 220 children in Cameroon whereby 18 analytes were 
determined in urine samples. Rubert et al. (2011) analysed OTA, DON, T-2, HT-2, ZEN, 
fumonisins and aflatoxins in urine of 27 volunteers.  
 
In contrast with most of these previously performed studies, the BIOMYCO study is the first 
study whereby a multi-toxin approach is applied for mycotoxin exposure assessment in 
adults and children on a large-scale. Moreover, it is the first study that described the 
exposure to an elaborated set of mycotoxins in the Belgian population. Additionally, studies 
using biomarkers to assess mycotoxin exposure in European children are – to the authors’ 
knowledge – not yet available. Finally, the BIOMYCO study described for the first time the 
used study design within a biomarker study in detail. 
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8.1.2 Prevalence of mycotoxins in Belgian urine 
 
In total, 394 urine samples from children and adults living in Belgium were analysed for the 
presence of 33 urinary mycotoxins and their metabolites. Nine out of 33 biomarkers were 
detected whereby DON(-glucuronides), DOMGlcA, OTA, CIT and HO-CIT were the most 
frequently detected. DON15GlcA was the main urinary metabolite found in 100 % of the 
samples and for the first time DOMGlcA was detected in urine of children. Furthermore a 
strong correlation was found between DON and its glucuronides. 
 
Recently, an increasingly number of studies became available whereby the exposure to 
mycotoxins in different European populations was assessed through urinary biomarkers (see 
section 3.3). Turner et al. (2008a) performed a pilot survey in the UK whereby 25 healthy 
adults participated. Urine samples were analysed for DON following β-glucuronidase 
treatment (LOQ 0.6 ng/mL). During consumption of the normal diet, all individuals had 
detectable urinary levels of DON, while fewer samples were positive (36 %) during the 
intervention. The geometric mean level during normal diet was 7.2 ng/mg creatinine. 
Additionally, Turner et al. (2010a) performed a pilot survey in male French farmers (n= 76) 
whereby DON was detected in 75/76 urine samples (0.5-28.8 ng/mL) and DOM-1 in 26/76 
samples (0.2-2.8 ng/mL). Warth et al. (2011) developed a LC-MS/MS method allowing 
quantification of both DON (LOD-LOQ 6-20 ng/mL) and DON3GlcA (LOD-LOQ 3-10 ng/mL) by 
a simple dilute and shoot approach. The applicability of the method was demonstrated 
through a pilot survey in Austrian adults whereby the average concentration of total DON 
(22 % free + 96 % glucuronides) was estimated to be 20.4 µg/L (max. 63 µg/L). DON15GlcA 
(LOD-LOQ 3.2-10.6 ng/mL) could be identified as a major DON metabolite in human urine 
based on the analysis of these samples. The results of the BIOMYCO project confirmed that 
glucuronidation of DON at the 15-position is the major detoxification route of DON in adults 
and children as earlier suggested by Warth et al. (2012a) and Huybrechts et al. (2014). 
Although we could not find DOM-1 in the Belgian urine samples, DOMGlcA was found in 22 % 
of the adults. This incidence is comparable with the 25 % found in the pilot survey 
performed in Belgium (Huybrechts et al., 2014). Our results confirm the suggestion that 
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DOM-1 derives from DON metabolism by intestinal microbiota, whereby not every person 
possesses this activity. After absorption, DOMGlcA can be formed followed by urinary 
excretion (Gratz et al., 2013). The incidence of DON and its glucuronides found in the 
BIOMYCO study are similar to the studies mentioned above, although the concentrations for 
the glucuronides are higher in Belgium. 
 
Munoz et al. (2010) developed a method that allows analysis of OTA (LOQ-LOQ 0.02-0.05 
ng/mL) and its detoxication product OTα (LOQ-LOQ 0.02-0.05 ng/mL) in urine. Application of 
the validated method in a pilot study with 13 volunteers from Germany revealed the 
presence of OTA (0.02-0.13 ng/mL) and OTα (0.05-4.7 ng/mL) in all samples. Duarte et al. 
(2010) evaluated the exposure of the Portuguese population (n= 155) to OTA (LOQ 0.008 
ng/mL) whereby 92.2 % of the urine samples were positive for OTA (mean 0.018 ng/mL). The 
OTA incidence in the BIOMYCO study was lower (35-51 %) than the incidence reported in 
these previous performed studies. No levels of OTα could be found in Belgian urine despite 
the low LOD of the used method. 
 
Blaszkewicz et al. (2013) developed a sensitive method for the analysis of CIT and HO-CIT in 
human urine and applied the method in a small pilot study in Germany. CIT was present in 
8/10 urines (0.05-0.2 ng/mL) and HO-CIT (LOD-LOQ 0.05-0.10 ng/mL) was detected in 5/10 
of the urine samples (0.15-1.12 ng/mL). Ali et al. (2014) applied the same method whereby 
CIT and HO-CIT were detected in 82 % and 84 % of all urine samples, at concentrations 
ranging from 0.02 to 0.08 ng/mL for CIT, and 0.05 to 0.51 ng/mL for HO-CIT. In the BIOMYCO 
study, the amount of positive samples was lower for CIT (59 %) although the concentrations 
were much higher (up to 1.4 ng/mL). The incidence of HO-CIT in the BIOMYCO study is much 
lower (6 and 12 %) despite the fact that the BIOMYCO study has a lower LOD.  
 
Aflatoxins, fumonsins and zearalenones (<1 %) could not be detected or quantified in urine 
samples from the Belgian population. This is in contrast with earlier performed studies. 
Solfrizzo et al. (2011a) developed a LC-MS/MS method for simultaneous determination of 
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AFM1, OTA, DON, DOM-1, α-ZEL, β-ZEL and FB1 in human urine. The developed method was 
further used in a survey with 52 volunteers from Southern Italy (Solfrizzo et al., 2014). The 
presence of ZEN + ZEL’s, OTA, DON, FB1 and AFM1 was detected in 100 % (0.120 ng/mL + 
0.176 ng/mL), 100 % (2.129 ng/mL), 96 % (67.36 ng/mL), 56 % (0.352 ng/mL) and 6 % (0.146 
ng/mL) of the samples, respectively. The BIOMYCO method was earlier pilot-tested in 32 
Belgian volunteers whereby urine samples contained the same mycotoxins as in the 
BIOMYCO study but no aflatoxins, fumonisines and zearalenones were found. Aflatoxins and 
fumonisins occur in hot and humid climates, which can be a reason why they do not occur in 
Belgian urine. 
 
8.1.3 Risk assessment 
 
The estimated intake for DON varies between 0.11 – 19.57 µg/kg BW/day for children and 
0.03 – 10.08 µg/kg BW/day for adults. Of total exposed subjects 56-69 % of children and 16-
39 % of the adults were estimated to exceed the TDI. The percentages exceeding the TDI for 
DON are much higher than previous estimations reported in Europe and could be due to the 
high consumption of different food products such as bread, beer and cornflakes. In a study 
performed in Austria dietary intake was estimated between 0.38 and 2.2 µg/kg BW/day 
whereby 33 % of these volunteers exceeded the TDI. Within the BIOMYCO study, 
DON15GlcA was quantified using the calibration curve of DON3GlcA without any correction 
for higher response. This could have led to an overestimation of the DON intake compared 
to the method whereby the concentration of DON15GlcA was corrected for the higher 
response by the factor 1.88 (Warth et al., 2012a). The calculations used in that study were 
based on daily urine production of 2 L instead of 1.5 L in our study. Sarkanj et al. (2013) 
analysed urine of 40 pregnant women in Croatia whereby the intake was estimated between 
0.1 and 33.1 µg/kg BW/day. Also in that study a daily urine volume of 2 L was used. 48 % of 
these women exceeded the TDI. Turner et al. (2010b) analysed 6 urine samples of 35 adults 
in the UK whereby 17 % exceeded the TDI (0.008 – 1.244 µg/kg BW/day). Gratz et al. (2014) 
analysed 2 urine samples of 15 adults in the UK and estimated the intake between 0.026 – 
0.918 µg/kg BW/day. Wallin et al. (2013) evaluated the exposure of DON in Sweden. The 
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DON intake varied between 0.002 en 5.448 µg/kg BW/day and only 1 % of the adults 
exceeded the TDI. Some of these performed studies (Turner et al., 2010b; Wallin et al., 2013) 
used the indirect method to measure DON-glucuronides. Interference of the used β-
glucuronidase with mucopolysaccharides and an incomplete hydrolysis, could be two 
reasons why these studies have lower intakes than the BIOMYCO study. On the other hand, 
most of these studies were performed on a limited number of participants and a limited 
number of toxins. Rodriguez-Carrasco et al. (2014b) analysed urine samples of 6 children, 16 
adolescents and 22 adults in Spain, but only studied DON and DOM-1 concentrations 
without hydrolysis. The DON intake was estimated between 0.06 and 1.07 µg/kg BW/day 
(8 % >TDI). Solfrizzo et al. (2014) analysed 52 urine samples of South-Italy with hydrolysis. 
When estimating the intake of DON, the assumption that 50 % of the ingested DON is 
excreted in urine was used instead of 72 % in the BIOMYCO study. The estimated mean 
intake was 5.90 µg/kg BW/day whereby 6 % of the adults exceeded the TDI. Differences in 
exposure could be explained to the different dietary habits between different countries and 
the higher occurrence of DON in temperate climates. All these different approaches to 
estimate the intake of DON make it difficult to compare the results between different 
countries and hence to know if the TDI is exceeded.   
 
For OTA the individually urinary level was used to carry out an exposure assessment. The 
estimated intake for OTA was between 0.2 – 100 ng/kg BW/day for children and  0.1 – 21 
ng/kg BW/day for adults. In total 1 % of the Belgian population exceeded the TDI for OTA. 
Solfrizzo et al. (2014) analysed 52 urine samples of South-Italy, whereby 94 % exceeded the 
TDI. The mean intake of OTA was calculated based on the assumption that 2.6 % of the 
ingested OTA is excreted in urine (Gambacorta et al., 2013) and was 0.139 µg/kg BW/day. 
The levels found in this study were higher than the levels found in the BIOMYCO project. This 
difference can be due to the fact that the consumption of wine and dried fruit is less in 
Belgium when comparing to South-European countries. Furthermore no OTA metabolites 
were found in the urine samples of the Belgian population, in contrast with other studies 
(Coronel et al., 2011; Munoz et al., 2010). This can have led to an underestimation of the 
OTA intake in Belgium.  
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The estimated total intake for DON and OTA could imply a health risk as 16 to 69 % of the 
cases exceeded the TDI for DON (depending on the approach applied to calculate the intake) 
and 1 % the TDI for OTA. It has to be highlighted that these calculations are based on 
assumptions (% urinary excretion) and that inter-individual variations were not taken into 
account. Due to the lack of toxicokinetic data on mycotoxins in human, there are still a lot of 
uncertainties that should be taken into account when perform a risk assessment based on 
urinary mycotoxin levels. Additionally, the presence of unknown metabolites can lead to an 
underestimation.  
 
In general, in this kind of exposure assessments young children need special attention 
because of the quantitative higher food intake per kg body weight. In order to perform more 
accurate estimations, more research needs to be done in order to collect more information 
about the human metabolism of mycotoxins, especially for CIT. More exposure assessment 
studies are needed in order to compare the different estimates and to evaluate the 
variability amongst people.  
 
8.1.4 Urinary biomarkers in relation to food consumption and socio-demographical 
characteristics 
 
Within the BIOMYCO study, exposure of different subgroups to DON, OTA and CIT was 
compared and differences between the mycotoxin concentrations measured for consumers 
and non-consumers of 43 food items was estimated, to explore whether the mycotoxin 
exposure could be explained by the consumption of certain foods.  
 
The urinary mycotoxin concentrations measured in the Belgian population differed 
significantly among age and gender. Additionally both negative and positive correlations 
were found between BMI and urinary mycotoxin levels in adults and children. A significant 
difference could be seen for diets, whereby children with only a West-European diet had 
higher levels of creatinine-adjusted DON in their urine in comparison with children who 
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followed a combination of different diets. A significant difference could be seen for pregnant 
women whereby the levels of CIT-equivalents were lower in comparison with non-pregnant 
women. Also the urinary levels of creatinine-adjusted OTA were lower for pregnant women. 
Additionally, no significant difference in exposure between smokers and non-smokers could 
be seen.  
 
Only a few studies investigated the differences of mycotoxin exposure between different 
subgroups on the one hand and the relation between urinary biomarkers and food 
consumption on the other hand. Ezekiel et al. (2014) conducted a study in Nigeria whereby 
AFB1 and FB1 levels in the food were significantly correlated with the excreted AFM1 and FB1 
respectively. Family exposure patterns based on urinary concentrations were observed for 
AFB1, FB1, OTA and ZEN (based on ZEN14GlcA). A study conducted in Spain showed 
differences in OTA urine levels at different stages of breastfeeding (Munoz et al., 2014) 
whereby higher OTA levels were found in infant urines collected a few days after delivery 
compared to samples collected from infants who consumed mature milk. In the same study 
a relationship between OTA intake with breast milk and OTA levels in urine of the infants 
was observed. Furthermore Sarkanj et al. (2013) performed a biomarker study in Croatia in 
order to identify trends in mycotoxin exposure of pregnant women. The analyses revealed 
an insignificantly higher exposure to DON of the rural subgroup compared to the urban 
subgroup. Due to the low sample number there were no statistically significant correlations 
found between food intake and urinary DON equivalents, BMI or age. Abia et al. (2013) 
investigated the difference in exposure between HIV negative and positive populations in 
Cameroon. Overall there was no significant difference between the mean concentrations of 
analytes among the subgroups. Despite all these studies a lot of questions still remain to 
understand which factors influence the exposure to mycotoxins and which subpopulations 
are at higher risk. 
 
In order to investigate the link between the presence of mycotoxins in urine and food 
consumption data, the population was divided in two classes for each food commodity 
(consumers and non-consumers). In a next step, the mycotoxin concentrations were 
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compared between the different classes whereby the consumption of 21 food items were 
related to higher/lower levels of OTA, DON, CIT, DON- and CIT-equivalents. The relationship 
between food consumption and urinary biomarker levels was earlier examined in the UK 
(Turner et al., 2010b). Within this study DON was assessed in first morning urine collected 
during a period of normal diet, a wheat-restriction intervention diet and partial wheat-
restriction intervention in which bread was allowed. A strong correlation was found between 
wheat intake and urinary DON. In another study performed in the UK (Turner et al., 2008c) 
cereal intake was significantly associated with urinary DON. In multivariable analysis 
wholemeal bread, white bread, other bread, buns/cakes, high-fiber breakfast cereal and 
pasta were significantly associated with urinary DON. In a study performed in Spain (Coronel 
et al., 2011) a correlation was found for OTA and OTα in urine and the consumption of 
possible contaminated food commodities. Ezekiel et al. (2014) conducted a study in Nigeria 
whereby AFB1 and FB1 levels in the food were significantly correlated with the excreted 
AFM1 and FB1 respectively. Furthermore Sarkanj et al. (2013) performed a biomarker study 
in Croatia where no statistically significant correlations found between food intake due to 
the small sample size. Additionally, urinary DON was associated with intake of total cereal 
grain as well as whole grain, breakfast cereals and porridge consumption in Sweden (Wallin 
et al., 2013).  
 
Some of the significant differences found in the BIOMYCO study could be explained by the 
earlier reported correlations with occurrences of mycotoxins in food commodities. On the 
other hand, these results raise questions regarding other dietary sources which contributed 
significantly to the urinary levels in the Belgian population. Any conclusion drawn at this 
phase of the research might be too preliminary. A ‘duplicate diet study’ whereby mycotoxins 
would be analysed in food consumed by a group of participants combined with a (24hours)-
urine collection should be ideal to further investigate the link found between urinary 
biomarkers and food consumption data.  
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8.2 STRENGTHS AND LIMITATIONS 
 
The major strength of this study was the large sample size and the representative 
distribution between age and gender across the study group to assess possible differences 
between mycotoxin exposure. This is further strengthened by including all the different 
classes of mycotoxins and a large amount of their metabolites with special attention to the 
glucuronides, the major urinary detoxification route in humans for DON. Furthermore, this 
study included young children aged from 3 until 12 years old which is of interest because of 
their quantitative higher food intake per kg body weight. This is further strengthened by 
collecting data on the consumption of 43 foods in order to get an idea about the 
consumption of several food items of interest. Furthermore the consumption of both the 
previous day and month before the urine collection was asked in order to get information 
about the relation to biomarkers with a short and long half-life. Finally, the BIOMYCO study 
is the first biomarker study performed in Belgium what is strengthened by the fact that for 
the first time a standardized study protocol was used and described. 
 
A first weakness of this study is the collection of only one urine sample per participant. 
Collecting one urine sample is useful to study the exposure at population level but does not 
give enough detailed information when studying the exposure at individual level. Collecting 
more urine samples per participant was not realistic as it was difficult to find people who 
wanted to participate. Additionally, collecting more samples was not feasible given the 
timeline and budget available in the BIOMYCO project. Second, no reference standards for 
the glucuronides were available and the quantification of DON15GlcA was based on the 
concentration of DON3GlcA, because of the small amount of standard available. Third, the 
inaccuracy of the reported food consumption as well as the limited list of food items 
included in the questionnaire could imply that not all important sources of mycotoxins in 
Belgium were identified. Fourth, the self-reported BMI could imply inaccurate results. Fifth, 
due to logistic and budget constraints we could not include children below 3 years old, 
teenagers between 13 and 18 years and elderly above 65 years. It is of interest to study the 
exposure to these subpopulations in the future. Finally, it has to be highlighted that it was 
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assumed that DON and CIT are excreted within 24 hours and OTA within 1 month after 
consumption when studying the link with food consumption. Next, the conversions of 
urinary concentrations to intake estimates were based on excretion rate assumptions and 
inter-individual variations were not taken into account.  Still a lot of toxicokinetic data about 
mycotoxins in humans is needed in order to circumvent the uncertainty of this type of 
analysis. A ‘duplicate diet study’ or an intervention study whereby mycotoxins would be 
analysed in the food and (24hours)-urine could be a better approach to study the relation 
between food consumption and mycotoxin exposure.  
 
 
[CHAPTER 9]  RECOMMENDATIONS FOR FUTURE 
 
 
108 |  
CHAPTER 9  
RECOMMENDATIONS FOR FUTURE RESEARCH 
 
 
Mycotoxins have already been known for many centuries, still a lot of research questions 
remain. Thanks to the evolution of technologies in sampling and mycotoxin analysis, more 
and more information is revealed about mycotoxin identification, occurrence, toxicology and 
their related risk for human and animal health.  
 
Sampling strategies 
 
From the available literature and information obtained during the BIOMYCO study it became 
clear that there is really need for alternative sample strategies. In most of the exposure 
assessment studies, mycotoxin biomarkers are analysed in morning- or 24-hours urine. 
While random spot samples are simple to collect, they are rarely equivalent to 24-hour 
collections due to analyte variability throughout the day. On the other hand, 24-hour 
collections are inconvenient and study participants tend to make collection and reporting 
mistakes, such as missed samples and errors in measuring total urine volume, which can 
affect results. Performing these sampling techniques on a large-scale becomes very difficult 
since both methods are subject to collection and transportation issues.  
 
A simple solution to eliminate most of the problems associated with liquid urine collections 
is to collect spot urine samples on filter paper. Dried urine sampling has been successfully 
applied for the determination of a wide range of compounds in different fields, such as 
toxicology and therapeutic drug monitoring (Barcenas et al., 2014; Lee et al., 2013) and 
could be useful in mycotoxin analysis where it is not yet available. Spot collections require 
no collection jug or refrigeration and improve sample transport and size. In developing 
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countries where most of the time no freezers are available, this sampling technique could be 
very useful. Urine dried on filter paper produces results nearly identical to liquid urine and 
several compounds and metabolites showed enhanced stability in dried urine spots 
compared with liquid samples as earlier reported (Carreno Balcazar and Meesters, 2014). 
Finally creatinine can also be measured in dried urine, providing a way to normalise results 
by using a correction factor taking into account hydration status (Antunes et al., 2013).  
 
Analytical methods 
 
The need for multi-mycotoxin analyses in biological matrices is constantly rising and the 
technology of choice is LC-MS/MS. A major challenge in mycotoxin biomarker research is the 
extremely low analyte concentrations present in biological fluids. Appropriate sample 
preparation protocols are crucial to obtain an acceptable sensitivity. However, polar 
conjugates such as glucuronides are frequently lost during common cleanup approaches. 
The available literature and the information obtained during the BIOMYCO study indicate 
that there is a lot of variability between the different methods regarding sensitivity and 
reported urinary biomarker levels. An important quality control measure is the use of 
certified reference materials. However, for mycotoxin biomarkers, there is no matrix 
reference material available that would make it possible to assess the measurement 
performance in the analysis of biologically important matrices such as human urine. 
Furthermore, the organisation of a proficiency test and the development of a standard 
method for the detection and quantification of mycotoxin biomarkers in urine samples will 
contribute to more accurate biomarker analysis.  
 
In the past, most biomarker methods focused on parent mycotoxins rather than on 
conjugated forms as no (certified) calibrants are commercially available for these 
metabolites. Furthermore, the targeted LC-MS/MS methods only analyse known mycotoxins 
and metabolites. In comparison with quadrupole instruments, the use of high resolution 
mass spectrometry such as time-of-flight increases the measured mass accuracy and 
resolution. This dominant tool for structural characterisation offers new opportunities in 
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mycotoxin research such as untargeted and metabolomic studies in order to reveal new 
metabolization patterns of mycotoxins in biological fluids.  
 
Mycotoxin risk assessment 
 
In order to study the impact of mycotoxin exposure on public health, it is important to assess 
the risk related to mycotoxin exposure. Currently, human exposure assessment to these 
toxins is often based on calculations combining mycotoxin occurrence data in food with 
population data on food consumption. In order to improve and refine risk assessments, 
human biomonitoring has become an added value in evaluating exposure to mycotoxins. The 
direct measurement of biomarkers of exposure is the only available tool that integrates 
exposures from all sources. Biomarkers of the most common mycotoxins have been 
validated in biological fluids such as urine. The individual variation in ADME processes is 
integrated when using biomarkers, whereby a more accurate assessment of exposure can be 
performed at the individual level. Furthermore, human biomonitoring can demonstrate 
trends and changes in exposure, establish distribution of exposure, identify vulnerable 
groups and it can reduce the assumptions regarding consumption rates. For this reason, the 
combination of exposure data from both methods will lead to a better interpretation in risk 
assessment (Choi et al., 2015).  
 
The major limitations of human biomonitoring are the lack of standardisation in 
methodology and the fact that human biomonitoring alone cannot provide information 
about the source of exposure. Comparison between different performed studies is difficult 
due to various factors such as differences in age, differences in detection limits, limited 
numbers of subjects in other studies and different analytical performances of the methods. 
A standardised study protocol should be implemented in order to compare the exposure of 
different populations. 
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Further efforts have to be taken to increase usability of human biomonitoring. In order to 
translate human biomonitoring data into daily exposure estimates there is need for detailed 
understanding of the toxicokinetics. Within the BIOMYCO study a risk assessment was 
performed by comparing the estimated dietary intake of DON and OTA with their TDI. The 
dietary intake of DON and OTA was estimated using the urinary concentrations. It has to be 
highlighted that the used calculations were based on a lot of assumptions and that inter-
individual variations in ADME processes were not taken into account. Due to the lack of 
information about the urinary mycotoxin excretion, no risk assessment could be performed 
for some of the mycotoxins. Still a lot of toxicokinetic and toxicological data about 
mycotoxins in humans are needed in order to circumvent the uncertainty of the statistical 
analysis, especially for CIT.  
 
Findings on the high prevalence of CIT and OTA observed in the BIOMYCO study highlight the 
need for more research concerning the exposure to these two toxins with focus on 
identifying other possible sources of mycotoxin exposure. Since fungal species are able to 
produce more than one mycotoxin, people are exposed to mixtures of mycotoxins. The 
additive, synergetic or antagonistic effects of mycotoxins and their influences on human 
health effects are still not well known and need to be further investigated. 
 
Some of the significant differences between consumers and non-consumers of different 
food commodities found in the BIOMYCO study could be explained by the earlier reported 
occurrences of mycotoxins in food commodities. On the other hand, the results raise 
questions regarding other dietary sources which contributed significantly to the urinary 
levels in the Belgian population. Any conclusion drawn at this phase of the research might be 
too preliminary. A ‘duplicate diet study’ whereby mycotoxins are analysed in food consumed 
by a group of participants or an intervention study whereby people need to follow a 
restricted diet, both combined with a (24hours)-urine collection could reveal more 
information to help with these questions.  
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Still a lot of questions remain to understand which factors influence the exposure to 
mycotoxins and which subpopulations are at higher risk. In general, further research should 
focus on exposure assessments in different subpopulations such as young children because 
of their relative high dietary intake per kg body weight or pregnant women because of the 
potential transfer of mycotoxins to the foetus.  
 
Finally, the determination of the variability of mycotoxin exposure amongst people using 
standardised study protocols and the analysis of the related uncertainties, could help policy 
makers to establish health based guidance values for mycotoxins in urine. Future research 
revealing more information about mycotoxin identification, occurrence, toxicology and their 
related risk could help risk managers to set recommendations for prevention and control of 
mycotoxins.  
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SUMMARY 
 
The manuscript entitled ‘Human biomonitoring of mycotoxin exposure through biomarker 
analysis’ describes the results of the BIOMYCO study whereby an exposure assessment of 
the Belgian population to mycotoxins was performed using urinary biomarkers of exposure. 
 
Mycotoxins are secondary metabolites produced by fungi. These naturally occurring toxins 
are important harmful food contaminants responsible for different toxicological effects. In 
the general introduction an overview of the main characteristics of aflatoxins, fumonisins, 
trichothecenes, ochratoxins, zearalenone (ZEN) and citrinin (CIT) are presented (Chapter 1). 
In Chapter 2, a detailed description is given about the toxicokinetics and the main 
toxicological effects of these toxins. Next, the formation of mycotoxin biomarkers, the 
existing analytical methods to measure mycotoxin biomarkers in urine and the available 
biomonitoring studies earlier performed were summarised (Chapter 3). 
 
In order to study the impact of mycotoxins on the public health, it is important to assess 
human exposure. Currently, human exposure assessment to these toxins is often based on 
calculations combining mycotoxin occurrence data in food with population data on food 
consumption. Because of uncertainties inherent to that approach, human biomonitoring has 
become an added value in evaluating exposure to mycotoxins in order to improve and refine 
risk assessments. The direct measurement of biomarkers of exposure is the only available 
tool that integrates exposures from all sources. Biomarkers of the most common mycotoxins 
have been validated in biological fluids such as urine. The individual variation in ADME 
processes is integrated when using biomarkers, whereby a more accurate assessment of 
exposure can be performed at the individual level. For this reason, the BIOMYCO study was 
designed to assess human mycotoxin exposure in Belgium using urinary biomarkers of 
exposure (Chapter 4).  
 
SUMMARY 
 
 
142 |  
Morning urine was gathered in a representative part of the Belgian population according to 
a designed study protocol, whereby 155 children (3-12 years old) and 239 adults (19-65 
years old) were selected based on random cluster sampling. Every participant completed a 
food frequency questionnaire to assess the consumption of relevant foodstuffs (n= 43) of 
both the day and month before the urine collection. The study protocol was approved by the 
ethical committee of Ghent University Hospital and is described in Chapter 5. 
 
A total of 394 urine samples were analysed for the presence of 33 potential biomarkers with 
focus on aflatoxins, CIT, fumonisins, trichothecenes, ochratoxin A (OTA), ZEN and their 
metabolites using two validated liquid chromatography tandem mass spectrometry (LC-
MS/MS) methods. Nine out of the 33 analysed mycotoxins were detected whereby 
deoxynivalenol (DON), OTA, CIT and their metabolites deoxynivalenol-3-glucuronide 
(DON3GlcA), deoxynivalenol-15-glucuronide (DON15GlcA), deepoxy-deoxynivalenol-
glucuronide (DOMGlcA) and dihydrocitrinone (HO-CIT) were the most frequently detected. 
DON15GlcA was the main urinary DON biomarker found and for the first time DOMGlcA was 
detected in children’s urine. Furthermore α-zearalenol and β-zearalenol-14-glucuronide 
were found in respectively one and two samples. Aflatoxin B1, aflatoxin B2, aflatoxin G1, 
aflatoxin G2, aflatoxin M1, fumonisin B1, fumonisin B2, fumonisin B3, hydrolysed fumonisin B1, 
diacetoxyscirpenol, 3-acetyldeoxynivalenol, 3-acetyldeoxynivalenol-15-glucuronide, 15-
acetyldeoxynivalenol, 15-acetyldeoxynivalenol-3-glucuronide, deepoxy-deoxynivalenol, 
fusarenon X, HT-2 toxin, ochratoxin α, T-2 toxin, ZEN, zearalenone-14-glucuronide, α-
zearalenol-7-glucuronide, α-zearalenol-14-glucuronide and β-zearalenol could not be 
detected or quantified in urine samples from the Belgian population. Additionally, other still 
unknown mycotoxin metabolites could be present in urine. Based on the urinary levels, the 
daily intake of DON and OTA was estimated and evaluated whereby, depending on the used 
method, 16-69 % of the population exceeded the tolerable daily intake for DON and 1 % for 
OTA (Chapter 6). These estimations, however, were based on a number of assumptions, and 
the results should therefore be interpreted with caution.  
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Exposure to DON, OTA and CIT was compared between subgroups (age, gender, …) whereby 
urinary mycotoxin concentrations measured in the Belgian population differed significantly 
among age and gender. Additionally a negative correlation was found between body mass 
index (BMI) and creatinine-adjusted levels of DON3GlcA and DON15GlcA and a positive 
correlation was found between BMI and creatinine-adjusted HO-CIT in adults. Furthermore a 
negative correlation was found between BMI and CIT in children using a Spearman 
correlation analysis. No significant difference in exposure between smokers and non-
smokers could be seen. Finally, a link between the mycotoxin concentrations measured and 
the food consumption reported was estimated, to explore whether the mycotoxin exposure 
could be explained by the consumption of certain foods (Chapter 7). Statistical analysis of 
food consumption data, revealed a link between urinary levels of DON, OTA and CIT and the 
consumption of some food commodities (21/43). However, it has to be remarked that these 
trends should be confirmed by future research.  
 
The BIOMYCO study is the first study whereby a multi-toxin approach was applied for 
mycotoxin exposure assessment in adults and children on a large-scale. Moreover, it is the 
first study that described the exposure to an elaborated set of mycotoxins in the Belgian 
population. Biomarker analysis showed a clear exposure of a broad segment of the Belgian 
population to DON, OTA and CIT. The risk assessment based on these data indicate a 
potential concern for a number of individuals whereby young children need special attention 
because of the relatively higher food intake per kg body weight (Chapter 8). The knowledge 
gathered through this study gives rise to new research questions and the need for future 
research (Chapter 9).  
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Het doctoraatsproefschrift getiteld ‘Human biomonitoring of mycotoxin exposure through 
biomarker analysis’ beschrijft de resultaten van de BIOMYCO studie waarbij de blootstelling 
van de Belgische bevolking aan mycotoxines in kaart werd gebracht door gebruik te maken 
van blootstellingsbiomerkers in urine. 
 
Mycotoxines zijn secundaire metabolieten die geproduceerd worden door schimmels. Het 
zijn natuurlijk voorkomende toxines die een belangrijke chronische risicofactor vormen in 
onze voedselketen en die verantwoordelijk zijn voor verschillende toxische effecten. In de 
algemene inleiding wordt een overzicht gegeven van de belangrijkste eigenschappen van 
aflatoxines, fumonisines, trichothecenen, ochratoxines, zearalenone (ZEN) en citrinine (CIT) 
(Hoofdstuk 1). In Hoofdstuk 2 wordt een gedetailleerde beschrijving gegeven over de 
toxicokinetiek en de belangrijkste toxicologische effecten van deze toxines waarna in 
Hoofdstuk 3 de vorming van mycotoxine biomerkers wordt samengevat. Tenslotte wordt 
een overzicht gegeven van de bestaande analytische methodes voor de bepaling van 
mycotoxine biomerkers in urine als ook van de beschikbare blootstellingstudies die eerder 
werden uitgevoerd. 
 
Om de mogelijke impact van mycotoxines op de volksgezondheid te bestuderen, is het 
noodzakelijk om de blootstelling van de bevolking aan deze toxines na te gaan. 
Blootstellingstudies zijn tot op heden gebaseerd op innameberekening op basis van 
concentraties van mycotoxines in voedingsmiddelen in combinatie met 
voedselconsumptiegegevens. Deze indirecte benadering heeft echter enkele onzekerheden, 
waardoor humane biomonitoring een meerwaarde is geworden bij het evalueren van de 
blootstelling. De directe meting van blootstellingsbiomerkers is de enige tool die 
blootstelling via verschillende routes integreert. Verder, kan er via de directe meting van 
blootstellingsbiomerkers in urine informatie verkregen worden over de individuele 
blootstelling aan mycotoxines. Een blootstellingstudie van de Belgische bevolking aan 
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mycotoxines via biomerkers was tot voor de start van dit project nog niet beschikbaar 
(Hoofdstuk 4).  
 
Ochtendurine van de Belgische bevolking werd verzameld volgens een vooraf opgesteld 
studieprotocol waaraan 155 kinderen (3-12 jaar) en 239 volwassenen (19-65 jaar) hebben 
deelgenomen. De nodige deelnemers werden door middel van clustersampling gerekruteerd. 
Alle deelnemers vulden ook een voedselfrequentievragenlijst in die peilde naar de inname 
van bepaalde relevante voedingsmiddelen (n=43) en de hoeveelheid ervan, zowel voor 24u 
als de maand voorafgaand aan de urinecollectie. Het studieprotocol werd goedgekeurd door 
het Ethisch Comité van het Universitair Ziekenhuis te Gent en wordt beschreven in 
hoofdstuk 5. 
 
In totaal werden 394 urinestalen geanalyseerd op de aanwezigheid van 33 potentiële 
biomerkers met focus op aflatoxines, CIT, fumonisines, trichothecenen, ochratoxine A (OTA), 
ZEN en hun metabolieten door gebruik te maken van twee gevalideerde 
vloeistofchromatografie tandem massaspectrometrische methoden (LC-MS/MS). Negen van 
de 33 mycotoxines werden gedetecteerd in de urine van de Belgische bevolking waarbij 
deoxynivalenol (DON), OTA, CIT en hun metabolieten deoxynivalenol-3-glucuronide 
(DON3GlcA), deoxynivalenol-15-glucuronide (DON15GlcA), deepoxy-deoxynivalenol-
glucuronide (DOMGlcA) en dihydrocitrinone (HO-CIT) het meest frequent werden 
teruggevonden. DON15GlcA bleek de belangrijkste urinaire DON metaboliet te zijn en werd 
in 100 % van de stalen teruggevonden. Voor de eerste keer werd ook het DOMGlcA 
gedetecteerd in de urine van kinderen. Verder werden α-zearalenol en β-zearalenol-14-
glucuronide teruggevonden in respectievelijk één en twee stalen. Aflatoxine B1, aflatoxine B2, 
aflatoxine G1, aflatoxine G2, aflatoxine M1, fumonisine B1, fumonisine B2, fumonisine B3, 
gehydrolyseerd fumonisine B1, diacetoxyscirpenol, 3-acetyldeoxynivalenol, 3-
acetyldeoxynivalenol-15-glucuronide, 15-acetyldeoxynivalenol, 15-acetyldeoxynivalenol-3-
glucuronide, deepoxy-deoxynivalenol, fusarenon X, HT-2 toxine, ochratoxine α, T-2 toxine, 
ZEN, zearalenone-14-glucuronide, α-zearalenol-7-glucuronide, α-zearalenol-14-glucuronide 
en β-zearalenol werden niet gedetecteerd in de urine van de Belgische bevolking. De 
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mogelijkheid bestaat echter dat er andere nog onbekende mycotoxine metabolieten 
aanwezig zijn in urine. Op basis van de urinaire concentraties van DON en OTA werd de 
blootstelling via voedselinname ingeschat. Deze blootstelling werd geëvalueerd waarbij, 
afhankelijk van de gebruikte methode, 16 tot 69 % van de Belgische bevolking de 
tolereerbare dagelijkse inname overschreed voor DON en 1 % voor OTA (Hoofdstuk 6). Deze 
innameschattingen zijn echter gebaseerd op een aantal veronderstellingen, waardoor deze 
resultaten met enige voorzichtigheid moeten geïnterpreteerd worden.  
 
De blootstelling aan DON, OTA en CIT werd vergeleken tussen verschillende subgroepen 
(leeftijd, geslacht, …) waarbij onder andere een significant verschil gevonden werd in 
urinaire mycotoxine concentraties naar gelang de leeftijd en het geslacht bij volwassenen 
en/of kinderen. Bijkomend werd een negatieve significante correlatie gevonden tussen de 
body mass index (BMI) en met creatinine-gecorrigeerde concentraties van DON3GlcA en 
DON15GlcA als ook een positieve significante correlatie tussen BMI en met creatinine-
gecorrigeerde concentraties van HO-CIT in volwassenen. Verder werd ook een negatieve 
significante correlatie gevonden tussen BMI en CIT in kinderen gebruik makend van de 
Spearman correlatie-analyse. Er werd geen significant verschil waargenomen tussen rokers 
en niet-rokers. Tenslotte werd er een verband tussen de gemeten mycotoxine concentraties 
in urine en de gerapporteerde consumptie van verschillende voedingsmiddelengroepen 
onderzocht om na te gaan of de blootstelling aan mycotoxines kon verklaard worden door 
de consumptie van bepaalde voedingsmiddelen (Hoofdstuk 7). Na de statistische analyse 
van de voedselconsumptiegegevens, kon een verband gezien worden tussen de urinaire 
concentraties van DON, OTA en CIT en de consumptie van enkele voedingsmiddelen (21/43). 
Deze resultaten moeten echter gezien worden als een eventuele trend die door verder 
onderzoek moet bevestigd worden. 
 
De BIOMYCO studie is de eerste studie waarbij een multi-toxine benadering werd gebruikt 
bij blootstellingstudies via urinaire biomerkers van volwassenen en kinderen op grote schaal. 
Verder is het ook de eerste studie die de blootstelling van de Belgische bevolking aan 
mycotoxines via biomerkers beschrijft. De biomerkeranalyse toonde een duidelijke 
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blootstelling van de Belgische bevolking aan DON, OTA en CIT. De risico-analyse gebaseerd 
op deze resultaten duidt een potentieel risico aan voor een aantal individuen waarbij 
speciale aandacht moet gegeven worden aan jonge kinderen gezien hun relatief hogere 
voedselinname in vergelijk met hun lichaamsgewicht (Hoofdstuk 8). De kennis die deze 
studie verzameld heeft, doet nieuwe onderzoeksvragen oprijzen en toont de nood voor 
verder onderzoek aan (Hoofdstuk 9). 
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Wat is uw geslacht ?
Man Vrouw
In welk jaar werd u geboren?
Wat is de postcode van uw huidige woonplaats?
1 / 2
SOCIO-DEMOGRAFISCHE GEGEVENS VOLWASSENEN
Wat is uw lengte (cm)?
Wat is uw gewicht (kg)?
ID-nummer
- 1 -
Geneesmiddel Dosis Geneesmiddel Dosis
Heeft u een ziekte of aandoening met betrekking tot ...?
(U kan meerdere antwoorden aanduiden. Indien u geen gezondheidsproblemen heeft, dan kan u
doorgaan naar de volgende vraag.)
Lever Gal Nieren Andere
Welke geneesmiddelen heeft u de VOORBIJE MAAND ingenomen? Welke dosis?
(Indien u geen geneesmiddelen neemt, dan kan u naar de volgende vraag doorgaan.)
Bent u zwanger of bestaat er een kans dat u zwanger bent?
Ja Neen
Geeft u borstvoeding?
Ja Neen
26321
Volgt u momenteel een dieet waarbij bepaalde voedingsmiddelen niet mogen gegeten
worden dit omwille van ziekte, allergie of zonder enige reden?
(U kan meerdere antwoorden aanduiden.)
Glutenvrij
Lactose-beperkt
Eiwit-beperkt
Energiebeperkt (vermagering)
Vet-/cholesterolarm
Zoutarm (Bijvoorbeeld bij hoge bloeddruk, ...)
Diabetes
Andere
Welk eetpatroon volgt u?
(U kan meerdere antwoorden aanduiden.)
Neen Ja, namelijk
West-Europees
Mediterraans
Oosters
Halal
Kosjer
Weinig vlees
Vegetarisch
Veganistisch
Andere
- 2 -
Rookt u?
Ja Neen
26321
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